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Abstract 
 
 
 
Resistance to antibiotics still poses a major challenge to human and animal health as a 
result of wide spread dissemination of resistance genes. Study of the evolutionary 
origin of these determinants is of importance in order to understand how the 
mechanisms involved arose in the first place. Two approaches were used to study 
antibiotic resistance from the evolutionary point of view; a model system of 
heterologous expression of Gram positive DNAs in a Gram negative background 
giving rise to macrolide resistance, and expression of the Gram positive glutathione-
S-transferase (gst) gene from Mycobacterium in both Gram positive and Gram 
negative backgrounds. 
 
Expression of the gst gene in Escherichia coli conferred a 3× increase in MIC in 
kanamycin and streptomycin and a ~ 2 fold increase for chloramphenicol. In the Gram 
positive Rhodococcus erythropolis ATCC 4277 it gave a ~ 5× increase in MIC for 
spectinomycin, streptomycin and nalidixic acid, while kasugamycin and 
chloramphenicol showed a 4× increase. Inactivation assay experiments also revealed 
the possibility of a novel chloramphenicol inactivation. Attempts made to create 
mutants with increased resistance by spontaneous selection, chemical mutagenesis or 
by use of an E. coli mutator strain were unsuccessful. 
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Chapter 1 
 
Introduction 
 
1.1 Actinomycetes 
 
Actinobacteria comprise bacteria whose common feature is the formation of hyphae at 
some stage of development. They are Gram-positive with a high GC content. 
Members of this group of bacteria can be found in most ecological settings, soil 
having the greatest population density, especially Streptomycetes (Taber, 1960; 
Gottlieb, 1973). They occur in greatest numbers in the top inches of the soil and 
decrease with depth (Waksman and Purvis, 1932). Other members colonize plants and 
animals, including some pathogens, such as Mycobacterium, Corynebacterium, 
Nocardia, Rhodococcus and a few species of Streptomyces.   
  
Most of the organisms in the order are aerobic, while some are facultatively anaerobic 
e.g. Actinomyces israelii and some strictly anaerobic species. Reproduction is usually 
asexual, though sexual processes have been shown to occur by genetic analyses. In 
the nonhyphal forms, asexual reproduction is by fragmentation or perhaps even by the 
usual fission of single cells. Where stable hyphae are produced, vegetative 
reproduction is by well formed spores resembling fungal arthrospores, borne either 
free or in sporangia.  
 
Actinobacteria are well known as secondary metabolite producers and as such, they 
are of high pharmacological and commercial interest as the major antibiotics 
producers (Sykes and Skinner, 1973). Except for a few antibiotics produced by fungi 
e.g. penicillin and cephalosporin, and a few from other bacteria e.g. bacitracin and 
polymyxin, most antibiotics that are medically useful and have a wide application are 
produced by the Actinomycetes. Other important roles of this group of bacteria (e.g. 
Streptomyces and Mycobacterium) include their activities in the soil where they 
function in decomposing the organic matter of the soil (Waksman and Lomanitz, 
1925; Reynold, 1954; Williams, 1966). They also exert their effect on the soil 
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structure in binding clay particles by their hyphal threads to impart a granular viable 
structure that is conducive to crop production. Actinomycetes are responsible for the 
earthy odour of soil (Gerber and Lechevalier, 1965). Other areas in which the 
production of the secondary metabolites by Actinomycetes has proved important 
include; their use as food preservatives, and incorporation into animal feeds with the 
primary effect of increasing the rate of growth in animals such as poultry, pigs and 
cattle. This is achieved by using the antibiotics to control low levels of infection in the 
animals and their effect on growth stimulation, specifically, in promoting the 
metabolism of the animals, thereby increasing hormone production, for example 
(Lucky, 1959; Wrenshall, 1959). 
 
1.2 Mycobacteria 
 
Mycobacteria usually occur as spherical or rod-like elements, though some species 
produce branched cells or even a branching mycelium (Besra et al., 1995). All strains 
contain mycolic acids, -branched -hydroxylated fatty acids (Sykes and Skinner, 
1973). Their cell wall is thicker than in many other bacteria, which is hydrophobic 
and waxy. The presence of arabinogalactan bridges in their cell wall connects the 
peptidoglycan layer with the mycolic acids, in which the galactose is in the five-ring 
furanose, rather than the common six-ring pyranose form (Besra et al., 1995). These 
organisms are nonmotile, nonsporulating, Gram-positive, aerobic rods. Their DNA 
base composition ranges from 60 to 65 mole percent GC (Frobischer et al., 1974). 
 
Many of these organisms grow on simple media with ammonia or amino acids as 
sources of nitrogen glycerol for the carbon source in the presence of mineral salts with 
varying optimum growth temperature between 25°C to over 50°C, but they are 
commonly cultivated on rich, solid organic media made with eggs, milk, and potatoes 
and containing selectively inhibitory dyes. When grown on simple media, the surface 
tension of the fluid must be lowered with a surfactant substance such as Tween 80 so 
that the fluid wets the waxy bacilli.  
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1.2.1 Pathogenicity of mycobacteria 
   
Although most species of mycobacteria are harmless saprophytes living in the soil, 
several species of mycobacteria are pathogenic for man and result in chronic, 
destructive granulomas which may undergo further necrosis with ulceration or 
cavitation. The roles of the obligate pathogens M. tuberculosis, M. bovis and M. 
africanum (tuberculosis causative agents), and M. leprae, M. microti (leprosy 
causative agents) are well known but in some areas the commonest infections other 
than those caused by M. tuberculosis are caused by strains of the M. avium-
intracellulare complex and the closely related species M. scrofulaceum (Runyon, 
1971).  
 
Another common pathogen, M. ulcerans, causes chronic skin lesions (Clancey, 1964; 
MacCallum et al., 1948; Perquis and Maret, 1965; Reid, 1967). Mycobacterial 
infections are difficult to treat since they are naturally resistant to a number of 
antibiotics that work by destroying cell walls because of their hardy cell wall which is 
neither truly Gram-positive nor Gram-negative and for this reason, they can survive 
long exposure to acids, alkalis, detergents, oxidative bursts, lysis by complement and 
antibiotics which naturally leads to antibiotic resistance. Most mycobacteria are 
susceptible to the antibiotics clarithromycin and rifamycin, but antibiotic-resistant 
strains are known to exist. 
 
1.2.2 Mycobacterium smegmatis 
 
Mycobacterium smegmatis was first described in 1884 by Lusgarten who found a 
bacillus with the staining appearance of tubercule bacilli in syphilitic chancres. 
Subsequently, Alvarez and Tavel found organisms similar to that in normal genital 
secretions (smegma), and it was later named M. smegmatis. It is generally considered 
a non-pathogenic microorganism; however in some cases it can cause disease, mainly 
in animals. In recent studies, it has been linked to the HIV virus and has been known 
to kill test animals (http://en.wikipedia.org/wiki/Mycobacterium_smegmatis). 
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The organism reduces nitrate, produces catalase, hydrolysis Tween, reduces tellurite, 
and grows in less than seven days at 37°C hence, classified as a rapid grower within 
the genus Mycobacterium (Frobischer, 1974). In molecular analyses, M. smegmatis 
has been an attractive model organism to work with because it can readily be grown 
in simple media and has been the preferred host for phage infections (Graham and 
William, 2000). It has been reported that strain mc2155 is readily transformable with 
integration-proficient plasmids and pAL5000-based episomal plasmids, and it readily 
undergoes homologous recombination, allowing for the generation of targeted gene 
disruptions. 
 
It has also been shown that genes from M. tuberculosis and M. leprae are readily 
expressed in M. smegmatis, allowing for the analysis of mycobacterial promoters and 
expression sequences. Numerous studies have also shown that mutations in the genes 
from M. smegmatis can be readily complemented with genes from M. tuberculosis or 
M. leprae thus proving mc2155 to be a valuable surrogate host. It is of great 
importance that multicopy expression of M. tuberculosis genes in M. smegmatis has 
provided a means of identifying the previously unknown targets of isoniazid, 
ethionamide, ethambutol, and pyrazinamide (Banerjee et al., 1994; Belanger et al., 
1996; Telenti et al., 1997). 
 
1.3 Glutathione S-transferase 
 
Glutathione (GSH) is a tripeptide of glutamic acid, cysteine, and glycine, the peptide 
link between glutamate and cysteine being on the -carboxyl. It is present in large 
amount in liver, muscle and other tissues. Its function is to establish a reducing 
situation in the cells and by virtue of its –SH group it is abbreviated to GSH. 
Glutathione is the most abundant low-molecular-weight cellular thiol in bacteria and 
eukaryotic cells, reaching levels of 1 to 10mM. Its major function include: the 
protection and detoxification of reactive chemical groups, by the high reactivity of its 
nucleophilic thiolate (Bernat et al., 1997; Elliot and Elliot, 2005). 
 
The reaction of glutathione S-transferases (GSTs) prevents carcinogenic molecules 
from reacting with DNA and causing genetic damage. GSTs have been grouped into 
at least twelve distinct classes on the basis of substrate specificity and primary 
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structure. The nomenclature is in flux due to the continued identification of new 
GSTs, particularly in prokaryotes. In prokaryotes few bacterial representatives have 
been characterized in detail and the catalytic activities and substrate specificities 
observed have generally been modest. The few well studied bacterial GSTs have 
largely unknown physiological functions (www.pubmedcentral.nih.gov/article). 
 
Prokaryotic GSTs are as diverse as their eukaryotic counterparts; they are broadly in 
prokaryotes as homodimers or heterodimers with ~25 kDa subunits. GSTs transform a 
wide variety of electrophilic compounds in a reaction typically involving GSH (-L-
Glu-L-Cys-Gly) conjugation. Glutathione detoxifies by donating a reducing 
equivalent (H+ + e-) to other unstable molecules such as reactive oxygen species in its 
reduced state. It then becomes reactive after donating an electron and readily reacts 
with another glutathione to form glutathione disulfide (GSSG).  
 
While most eukaryotic GSTs consume a single GSH that is conjugated to an 
electrophilic substrate during catalytic turnover, bacterial GSTs display considerable 
diversity with respect to the utilization of GSH in their detoxification and catabolic 
pathways functions. For example, enzymes such as maleylacetoacetate and 
maleypyruvate isomerases utilize but do not consume GSH. Some bacterial GSTs, 
such as tetrachloro-hydroquinone (TCHQ) dehalogenase from Sphingomonas 
chlorophenolica, consume two GSH equivalents. The first being used in the 
dehalogenation step leading to the formation of a mixed disulfide with the enzyme, 
and the second to regenerate the free enzyme, yielding a disulfide-bridged product, 
GSSG i.e. oxidized glutathione (Tocheva et. al., 2006).  
 
 
Glu-Cys-Gly 
| 
SH 
Fig. 1a Reduced glutathione (GSH) 
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Glu-Cys-Gly 
| 
S 
| 
S 
Glu-Cys-Gly 
 
Fig. 1b Oxidized glutathione (GSSG) 
 
1.4 Mutagenesis 
 
Mutagenesis is a process through which a change in the heritable characters is 
introduced into an organism. This change is not a result of transfer, segregation, or 
recombination of normal genes but of an alteration of the numbers, molecular 
structure or sequence of nucleotides that constitute the genes themselves. Mutations 
can arise spontaneously or be induced by mutagenic agents. Spontaneous mutations 
arise from errors in replication, spontaneous lesions, or transposition events. 
Replication errors can result in base pair substitutions. In transitions, a purine is 
replaced by a purine or a pyrimidine by a pyrimidine. In transversions, a purine is 
replaced by a pyrimidine and a pyrimidine by a purine. For the frameshift mutations, 
the codon frame is altered by deletion or addition of a single base pair to the 
sequence, and this can result in greatly altered protein products.                                                                                 
 
Induced mutations are those caused by the action of a specific mutagen. Each 
mutagen exhibits specificity, usually the result of the mechanism by which the 
mutagen alters the DNA. There are three basic mechanisms of induced mutagenesis; a 
base is replaced by another base, a base is altered so that it mispairs with another base, 
or a base is damaged so that it can no longer pair with any base (Graham and William, 
2000). Mutagenic agents that cause induced mutations could be physical agents like a 
very high temperature, gamma radiation which has been used to induce mutations in 
M. phlei, an ultra violet light, or by chemical mutagens (Kolman and Herenberg, 
1978). Konickova-Radochova et al., 1970 identified a wide range of effective agents 
as chemical mutagens and such include; acriflavin, ethyl methanesulfonate (EMS), 
hydroxylamine, nitrous acid, N-methyl-N-nitro-N-nitrosoguanidine (NTG).  
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In vitro mutagenesis is a method for the generation of random point mutations in a 
given DNA segment. The DNA region to be mutagenized is amplified with a 
technique under such conditions that reduce the fidelity of DNA synthesis by Thermus 
aquaticus (Taq) DNA polymerase (Leung et al., 1989), and the technique is referred 
to as an error prone polymerase chain reaction (epPCR). This method of mutagenesis 
is a powerful tool for the study of structure and function of both proteins and 
regulatory DNA elements (Botstein and Shortle, 1985). 
 
1.5 Antibiotics 
 
Antibiotics are low molecular weight substances which have the ability in dilute 
solution to inhibit pathogenic bacteria (bacteriostatic effect) or to kill them 
(bactericidal effect). They are secondary metabolic products from microorganisms 
and they act by blocking some crucial processes in a prokaryotic cell without having a 
harmful effect on the infected host. Most antibiotics have a molecular weight of < 2 
kDa. They may be natural products, semi-synthetic or synthetic chemicals. The 
existence and clinical development of both synthetic and natural product antibiotics 
reflect a dichotomy in antibiotic discovery programs in the 20th century. At one end of 
the spectrum was the medicinal chemistry view and at the other was the classical 
“magic bullet” approach that pure compounds could be made with therapeutic 
specificity and utility. The early introduction of the sulfa drugs as antibacterials, still 
in use six decades later, was an early success for this approach (Amyes, 2001). 
 
Antibacterial agents can be classified on their target specificity: “narrow spectrum” 
antibiotics which target particular types of bacteria, such as Gram-negative or Gram-
positive bacteria. Other factors to be considered while investigating these compounds 
include; the economic impacts, the bacterial disease they are prescribed for and their 
mode of action, which is the principal criterion for classifying them (Tipper and 
Strominger, 1965; Gale, 1981; Russell and Chopra, 1996). 
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1.5.1 Classes of antibiotics 
 
With respect to their specific target sites in microorganisms, antibiotics are classified 
into four major groups; (i) cell wall biosynthesis e.g. penicillin, a member of -lactam 
class, (ii) protein biosynthesis e.g. erythromycins and clindamycin, members of the 
macrolide class, (iii) DNA replication/repair e.g. ciprofloxacin, a member of the 
quinolone class, and (iv) RNA synthesis e.g. rifampicin, one of the rifamycins (Ali et 
al., 1989; Retch and Puglisi, 2001). 
 
1.5.1.1 Antibiotics that act on cell wall biosynthesis 
 
This class of antibiotics interdicts any of the several steps in bacterial cell wall 
assembly, from biogenesis of the specialized assembly, membrane translocation, and 
extracellular cross-linking and strengthening of the exoskeletal peptidogycan layers 
(Walsh, 2003). Many of the antibiotics that affect bacterial cell walls inhibit enzymes 
or sequester substrates involved in peptidoglycan assembly and cross-linking. The 
thick peptidoglycan layer of Gram-positive bacteria has been described as a surface 
organelle, for display of   carbohydrates and proteins, while the outer membrane is the 
equivalent surface organelle in Gram-negative organisms (Lee and Schneewind, 2001; 
Navarre and Schneewind, 1999; Nikaido, 1994). 
 
Gram-positive bacteria are susceptible to some antibiotics that do not work or work 
poorly against Gram-negative bacteria (e.g. pseudomonads), and this difference is 
related to the ability of antibiotics to be blocked by the limiting pore sizes of the porin 
proteins of the Gram-negative organisms’ outer membranes (Koebnik et al., 2000). 
There is no such barrier to diffusion in Gram-positive bacteria. Penicillin, a member 
of the -lactam antibiotics, cephalosporins and ampicillin are well known examples of 
this class of the antibiotics (Lund and Tybring, 1972; Tipper and Strominger, 1965). 
 
1.5.1.2 Antibiotics that block bacterial protein biosynthesis 
 
The antibiotics in this class exert their bacteriostatic or bactericidal action by blockage 
of one or more of the protein biosynthesis steps that occur on the 30S and 50S 
subunits of the bacterial ribosome. Bacterial ribosome is a two-subunit nucleoprotein 
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particle, about two-thirds RNA and one-third protein, of molecular weight 2.5 to 2.6 
MDa (Yusupov et al., 2001). The small subunit, 30S, contains about 20 proteins and a 
16S ribosomal rRNA of about 1,500 ribonucleotides. Streptomycin and neomycin, 
aminoglycosides, are examples of antibiotics that target this ribosomal unit (Retch and 
Puglisi, 2001). Those that bind the large subunit belong to the macrolides e.g. 
streptogramin B and lincosamides (Malbruny, et al., 2004; Motanari, et al., 2003). 
Chloramphenicol, the principal antibiotic in my work, also blocks bacterial protein 
synthesis as an amino acid antimetabolite. Binding occurs in the peptidyltransferase 
center of the 50S ribosome subunit (Walsh, 2003). 
 
1.5.1.3 Antibiotics that block DNA replication/repair 
 
Natural products from metabolic activities in bacteria have the ability to inhibit DNA 
replication and repair enzymes, resulting in the death of the other bacteria in the 
neighbourhood. The coumarins as represented by such streptomycetes metabolites as 
novobiocin and coumermycin target DNA type II topoisomerases, specifically DNA 
gyrase (Maxwell, 1997). DNA gyrase is important for controlling DNA topology in 
DNA replication, recombination, and transcription, while topoisomerases IV is also 
implicated in DNA replication and decatenation of linked daughter chromosomes at 
the end of bacterial DNA replication (Pan and Fisher, 1997). 15 quinolones have been 
evaluated against S. aureus MS 5935 and subdivided into three classes; (i) those that 
target topo IV preferentially e.g. norfloxacin, ciprofloxacin and levofloxacin, (ii) 
those that are more selective for DNA gyrase e.g. sparfloxacin and nadifloxacin, and 
(iii) those that target topo II and topo IV equally e.g. gatifloxacin and moxifloxacin 
(Takei et al., 2001) 
 
Rifampicin which is a member of the rifamycins is an example of antibiotics that 
block RNA synthesis and they are very useful in the treatment of tuberculosis. Other 
antibiotics of clinical importance not mentioned in the above major classes include 
those that block precursor biosynthesis for nucleic acids as well as those that act to 
disrupt one or more aspects of bacterial membrane functions. Antibiotics that exert 
their activity by permeabilizing bacterial membranes include the antimicrobial 
peptides e.g. tigerinins (Sai, 2001).                                                                                                     
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Those that block folic acid metabolism include the synthetic sulfa drugs e.g. 
sulfamethoxazole, used in combination with trimethoprim for the treatment of patients 
with urinary tract infections and also for AIDS patients with Pneumocystis carinii 
infections (Scholar and Pratt, 2000). Sulfamethoxazole blocks the enzyme 
dihydropteorate synthesase in the biosynthetic pathway to folate, while trimethoprim 
inhibits dihydrofolate reductase, a key enzyme providing the pyrimidine thymidylate 
for DNA biosynthesis. 
 
1.6 Mechanisms of antibiotic resistance 
 
It has been widely reported that since the development of antibiotics, the drug-
producing microbes have also developed intrinsic resistance mechanisms of 
protection to avoid self-destruction during antibiotic production. Such mechanisms 
include; modification of the susceptible molecular target, efflux of the antibiotic, and 
response to antibiotic challenge by inactivation of the drug. Protein modification have 
been found in penicillin-binding proteins which underlie the methicillin-resistant 
Staphylococcus aureus (MRSA) phenotype, also 23S rRNA methylation is prevalent 
in erythromycin resistance, and reprogramming of peptidoglycan intermediates in 
vancomycin resistance. 
 
Antibiotic resistance genes such as mef A, mef E and mre A code for transport (efflux) 
proteins which pump the antibiotic out of the cell, keeping intracellular concentrations 
low and ribosomes free from antibiotic. The pumps act through proton- or ATP- 
driven membrane transporters, this mechanism is of major importance in the 
macrolide resistance (Giovanetti et al., 2002; Motaneri et al. 2003; Walsh, 2003). 
 
Dabbs reported in 2004 that four mechanisms were identified in rifampicin 
inactivation enzymes and they include; decomposition, ribosylation, glucosylation and 
phosphorylation. Although the first report of rifampicin modification enzymatic 
activity was in Rhodococcus rhodococcus and in M. smegmatis (Dabbs, 1987), 
enzymatic inactivation of antibiotics occurs with several of the natural product 
antibiotic classes, but has not yet been observed as a major route of resistance 
development for the classes of synthetic antibacterials e.g. the fluoroquinolones and 
the oxazolidinones. The most wide spread of clinical development to -lactam 
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antibiotics is the expression of -lactamase that hydrolyze the antibiotic (Bush and 
Mobashery, 1998). 
    
1.7 Evolution of antibiotic resistance 
 
The growing health crisis of antibiotic resistance has been of concern over the years. 
During the five to six decades that antibiotics have been in ever-widening therapeutic 
use, the development of antibiotic resistance has followed. The intensive and 
essentially constant exposure of bacteria to antibiotics has led to selective pressure for 
antibiotic-resistant bacteria to maintain those determinants, survive, and even 
dominate the bacterial populations (Walsh, 2003). It has been reported that 
spontaneous mutations (although infrequent) in the bacterial chromosome may 
modify the target site of the antibiotic thus interfering with normal function of the 
target site and they are passed on to all of the bacterial progeny (Schnappinger et al., 
1996). 
 
Bacteria have been so evolutionary successful because of their fast generation time, 
large population sizes and unique method of gene acquisition. Bacteria are capable of 
exchanging resistance genes among nearby bacterial cells by horizontal gene transfer, 
referred to as conjugation. Such genes could also be disseminated among bacterial 
population through the uptake of extacellular DNA, the process known as 
transformation, and there could be genetic material transfer through infections of 
bacteria by virus (transduction). 
 
Human behaviour in the excessive and wrong use of antibiotics has also contributed 
largely to the rapid increase in the resistance to antibiotics. Kunin, 1993 reported that 
excessive use of antibiotics in ambulatory practice has contributed to the emergence 
and spread of antibiotic resistance in the community. This ranges from unnecessary 
medical prescriptions, to the prophylactic use in livestock to promote growth in 
healthy animals.  
 
It has been established that some livestocks were given animal feed containing 
avoparcin, and humans coming into contact with the animals have been shown to 
carry vancomycin-resistance enterococci. The public health concern about the 
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emergence  and dissemination of this resistant strain in food animals and the food 
supply caused the European union to ban the use of avoparcin in animal feed in 1997 
(Hammerum, et al., 2000; Manson, et al., 2003; Witte, 1998). It is now a major 
concern that infection from penicillin resistant pneumococci has increased at an 
alarming rate during the past two decades, particularly the last five years. It is more of 
a concern that many of these resistant pneumococci also exhibit resistance to 
chloramphenicol, co-trimoxazole, macrolides and tetracycline (Appelbaum, 1995). 
 
Inappropriate use of antimicrobials by exposure to low and/or prolonged 
concentrations also has a role in the selection of resistance. This may occur by killing 
susceptible normal flora and allowing pre-existing resistant organisms to survive, or 
by increasing the likelihood for subsequent colonization of the host with resistant 
bacteria (Guillemont, et al., 1998; Morita et al., 2000).  
 
1.7.1 Erm genes 
 
Two examples will be given where the origin of resistant determinants is known. One 
of the earliest discoveries in the evolution of antibiotic resistance mechanisms is the 
alteration of the rRNA structure, by single base mutations. This mutation involves the 
A2058 adenine or one of the adjacent residues (A2057 or A2059) in the peptidyltransferase 
loop in domain V of the 23S rRNA. An X-ray determination of the 50S subunit of the 
ribosome soaked with erythromycin visualized the antibiotic bound in the 
peptidyltransferase cavity, in the vicinity of both A loops and P loops, and near A2058. 
This action is monomethylation or dimethylation of the N6 exocyclic amino group of 
A2058 by a gene known as erythromycin ribosome methylation (erm) gene, the 
modification enzyme by the gene produces the Erm phenotype and reduced affinity of 
the RNA for the antibiotic, without affecting the role of A2058 in peptidyltransferase 
function (Walsh, 2003). 
 
Over the last 30 years, a large number of different rRNA methylase genes have been 
isolated from a variety of bacteria that range from E. coli to Haemophilus influenzae 
in Gram negative species, and from Streptococcus pneumoniae to Corynebacterium 
spp. in Gram positive species (Roberts et al., 1999). There are many cellular N-
methyltransferases known, including RNA N-methyltransferases, and evolution of the 
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Erm methyltransferases from such a precursor is likely. In particular ermE is a 
constitutively expressed enzyme of the erythromycin biosynthesizer 
Saccharopolyspora erythraea, where it provides protection to the antibiotic producer 
and may be a recent progenitor of the erms in the resistant pathogens. 
 
The methyl-A2058-specific enzymatic modification in 23S rRNA not only decreases 
affinity for macrolide antibiotics of the erythromycin class, but also for those of the 
lincomycin/clindamycin class, as well as for a third group, the streptogramin B 
(MLSB) phenotype of ribosomal drug resistance. Many of the erm genes occur on 
conjugative or non-conjugative transposons, on chromosomes or sometimes plasmids. 
They are often associated with other antibiotic resistance genes, especially those 
against tetracycline (Clewell et al., 1995; Salyer et al., 1995). 
 
While the ermE enzyme in S. erythraea is produced constitutively, the MLSB 
phenotype is usually inducible by erythromycin resistant pathogens. Studies have also 
revealed that one of the erm genes, the ermC gene transcription in Staphylococcus 
aureus indicate that a 141-bp leader sequence just upstream of the ermC start codon 
adopts a secondary structure that sequesters the ribosome binding site so ermC 
transcription is blocked. In the presence of low level erythromycin, the secondary 
structure of the leader is postulated to refold, exposing the ribosome binding site, 
permitting ermC transcription, and producing ErmC methytransferase which 
methylates A2058 and protects the ribosome before lethal concentrations of 
erythromycin build up in the cell (Walsh, 2003). 
 
1.7.2 Aminoglycoside phosphotransferase 
 
Bacterial resistance to aminoglycoside antibiotics is mediated primarily by covalent 
modification of these drugs by a variety of enzymes. One such modifying enzyme, the 
3´-aminoglycoside phosphotransferase, produced by Gram positive cocci such as 
Enterococcus and Streptococcus, inactivates a broad range of aminoglycosides by 
ATP-dependent phosphorylation of specific hydroxyl residues on the antibiotics. 
(Mckay and Wright, 1995). 
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Aminoglycosides read specific regions of the 16S rRNA in the 30S ribosome subunit 
by a hydrogen bonding network through the various hydroxyl and amino substituent 
on the cyclitol rings to provide a high-affinity docking site for this class of antibiotics. 
The enzymatic destruction strategy for aminoglycoside-resistant bacteria is to 
covalently modify those specificity-conferring hydroxyl and amino groups in the 
aminoglycosides and thereby interfere with recognition by the 16S rRNA 
(Livermoore, 2000; Poole, 2001). This kind of enzymatic modifications of the 
hydroxyl and amino groups on aminoglycosides is of normal electrophilic group 
transfer enzyme that participates in primary metabolism (Kotra et al., 2000; Wright, 
1999). 
 
ATP is a reactant used in O-phosphoryl transfers, by attack of the -PO3 group by a 
hydroxyl or amino nucleophile and the reaction is irreversible. Other kinds of 
enzymatic modifications of hydroxyl and amino groups on aminoglycosides include; 
adenylylation and acetylation. It is likely that the antibiotic-inactivating enzymes will 
have evolved from phosphotransferases, adenyltransferases and N-acetyltransferases 
that had been utilized for normal biosynthetic process in the bacterial cells. 
 
The determination of X-ray structure of the APH (3’)-IIIa phosphotransferase from 
enterococci revealed high similarity to eukaryotic serine/threonine protein kinases, 
consistent with an evolution from protein substrate –OH recognition for attack on the 
-PO3 of ATP to recognition of the aminocyclitol framework –OH under selective 
pressure to survive (Hon et al., 1997). Given the multiplicity of hydroxyl and amino 
groups in the successive generations of aminoglycosides to see clinical use, it is not 
surprising that modifying enzymes of distinct regiospecificity for phosphorylation, 
acetylation and adenylylation would arise. The presence of the genes for modifying 
enzymes on transmissible plasmids helps spread the resistance determinants and 
perhaps speed the evolution of catalytic activities toward newly introduced 
aminoglycosides. 
 
 
 
 
 15 
1.8 Chloramphenicol 
 
The antibiotic chloramphenicol was isolated from Streptomyces venezuelae in 1948 
(Malik, 1972; Vining and Stuttard, 1995). It is a bacteriostatic antimicrobial which 
was introduced into clinical practice in 1949. It was widely used for some decades as 
a broad spectrum antibacterial agent, active against both Gram-negative and Gram-
positive bacterial infections by blockage of bacterial protein synthesis as an amino 
acid antimetabolite. It was the first antibiotic to be manufactured synthetically on a 
large scale. Though it has fallen out of favour in the West due to very rare but serious 
side effects, but is still very widely used in low income countries because it is very 
inexpensive. It has been recently discovered to be a life saving cure for 
chytridiomycosis in amphibians (http://en.wikipedia.org/wiki/chloramphenicol). 
 
1.8.1 Mode of action of chloramphenicol 
 
The antibiotic functions by inhibiting peptidyl transferase activity of the bacterial 
ribosome, binding to A2451 and A2452 residues in the 23S rRNA of the 50S 
ribosomal subunit. It directly interferes with substrate binding, and is a simple 
molecule with a nitrophenyl serinol skeleton in which the amino group has been 
acylated with a dichloroacetyl group. The backbone clearly comes via the chorismate 
pathway, via amination, to produce 4-amino-4-deoxychorismate, that on 3, 3-
sigmatropic rearrangement and dehydrogenative aromatization gives para-
aminophenylalanine.       
 
The conversion of the -CH2 to the CHOH of aminophenylserine probably also 
occurs while the amino acid is installed on an A-PCP reductase three-domain subunit. 
The aminophenylseryl-S-PCP would then be reductively cleaved by the third domain 
in the protein to release the aminophenylserol. This is two steps away from the 
antibiotic. One is the dichloroacetylation, presumed to occur from dichloroacetyl-CoA 
(Vining and Stuttard, 1995) and the other is the N-oxidation of the para-amino to 
para-nitro substituent. Some of the logic and mechanism of nonribosomal peptide 
synthetase selection, activation, and modification of amino acid monomers is utilized 
in these amino acid-based antibiotics (Walsh, 2003). 
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Fig. 2: Structure of chloramphenicol 
Chemical formula: C11H12Cl2N2O5 
Compound name: 2,2-dichloro-N-[(aR,bR)-b-hydroxy-a-hydroxymethyl-4-nitro 
phenethyl] acetamide 
(http://www.freebase.com/view/wikipedia/images/commons_id924397) 
1.8.2 Clinical uses of chloramphenicol 
 
Because it functions by inhibiting bacterial protein synthesis, chloramphenicol has a 
very broad spectrum of activity: it is active against Gram-positive bacteria (including 
most strains of MRSA), Gram-negative bacteria and anaerobes. The original 
indication of chloramphenicol was in the treatment of typhoid, but the now almost 
universal presence of multi-drug resistant Salmonella typhi has meant that it is seldom 
used for this indication except when the organism is known to be sensitive. It may be 
used as a second-line agent in the treatment of tetracycline-resistant cholera. Due to 
its excellent CSF penetration (far superior to any of the cephalosporin), it remains the 
first choice treatment for staphylococcal brain abscesses. 
 
It is also helpful in the treatment of brain abscesses due to mixed organisms or when 
the causative organism is not known. The antibiotic is active against the three main 
bacterial causes of meningitis: Neisseria meningitides, Streptococcus pneumoniae and 
Haemophilus influenzae. In the West, chloramphenicol remains the drug of choice in 
the treatment of meningitis in patients with severe penicillin or cephalosporin allergy. 
In low income countries, the World Health Organization recommends that oily 
chloramphenicol be used first-line to treat meningitis. In the U.S., it has been used in 
the initial empirical treatment of children with fever and a petechial rash, when the 
differential diagnosis includes Neisseria meningitidis and septicaemia, as well as 
 17 
Rocky Mountain spotted fever, pending the results of diagnostic investigations. The 
antibiotic is also effective against Enterococcus faecium, which has led to it being 
considered for treatment of vancomycin-resistant Enterococcus 
(http://en.wikipedia.org/wiki/chloramphenicol).                                                           
 
1.8.3 Side effects of chloramphenicol 
 
The most serious side effect of chloramphenicol treatment is aplastic anaemia, though 
the effect is rare, but it is generally fatal and has no treatment (Rich et al., 1950). 
There is no way of predicting who may have this side effect, it usually occurs weeks 
or months after the treatment has been stopped and there may be a genetic 
predisposition (Nagao and Maner, 1969). It is not known whether monitoring the 
blood counts of patients can prevent the development of this effect, but it is 
recommended that patients have a blood count checked twice weekly while on 
treatment. The highest risk is with oral chloramphenicol (affecting 1 in 24,000 - 
40,000) and the lowest risk occurs with eye drops (affecting less than 1 in 224,176 
prescriptions).                                                          
 
It is also common for chloramphenicol to cause bone marrow suppression during 
treatment. This is a direct toxic effect of the drug on the human mitochondria, but the 
effect is fully reversible once the drug is stopped and does not predict future 
development of aplastic anaemia. Intravenous chloramphenicol use has been 
associated with the so called gray baby syndrome, the phenomenon that occurs in 
newborn infants because they do not yet have fully functional liver enzymes, it 
therefore remains unmetabolized in the body and causes hypotension and cyanosis. 
The condition can be prevented by using chloramphenicol at the recommended doses 
and monitoring blood levels (Muhall et al., 1983).          
             
1.8.4 Chloramphenicol resistance mechanisms 
 
There are three mechanisms of resistance to chloramphenicol: reduced membrane 
permeability, mutation of the 50S ribosomal subunit and elaboration of 
chloramphenicol acetyl transferase. Resistance-conferring mutations at 50S are rare, 
and it is easy to select for reduced membrane permeability to the antibiotic in vitro by 
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serial passage of bacteria and this is the most common mechanism of low-level 
chloramphenicol resistance. The high level resistance is conferred by the cat-gene; 
this gene codes for an enzyme called chloramphenicol acetyl transferase which 
inactivates chloramphenicol by covalently linking one or two acetyl groups, derived 
from acetyl-S-coenzyme A, to the hydroxyl groups on the chloramphenicol molecule. 
The acetylation prevents the antibiotic from binding to the ribosome. 
Chloramphenicol resistance may also be carried on a plasmid that also codes for 
resistance to other drugs e.g. ACCoT plasmid, also called the R factors, and it 
mediates multi-drug resistance in typhoid. 
 
1.9 Aims and objectives 
 
Antibiotic resistance remains a major threat to human and animal health as a result of 
wide spread dissemination of resistance genes. These genes had existed long before 
the use of antibiotics: they have been detected in coliforms from glacial water and ice 
estimated at 2000 years old, evidence also suggests that R-genes long predate the use 
of antibiotic in medicine, evolving long ago in soil bacteria (Skinner et. al., 1983; 
Dancer et. al., 1997). 
 
Study of the evolutionary origin of antibiotic resistant determinants is a key role in the 
determination of how the resistance evolved in the first place, and then to understand 
how the mechanisms have developed, hence the need for more work in this area of 
research.  
 
In her work, Dorothy Nteo (2006) described a model system of heterologous 
expression of Gram positive DNA in a Gram negative background, thus providing 
another perspective of studying antibiotic resistance from an evolutionary perspective. 
The aim of this work therefore, was to express the DNA of a glutathione S-transferase 
gene from Mycobacterium smegmatis mc2155 strain in different bacterial strains, and 
to obtain a mutant that would be used for molecular analysis with respect to antibiotic 
resistance. The DNA was from the clone pDN1 prepared by Duduzile Ndwandwe. 
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The specific objectives in this work include the following: 
 
 expression of the gst gene in the Gram negative background; 
 expression of the gst gene in the Gram positive background; 
 phenotypic characterization of the clones from these bacterial strains; 
 molecular analysis of the clones; 
 carrying out mutagenesis on the clones; and   
 characterization of additional clones from the libraries screened by Dorothy Nteo 
for macrolide resistance. 
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Chapter 2 
 
Materials and Methods 
 
2.1 Bacteria strains and plasmid vectors used in this work 
 
Table 1: Bacteria strains used in this work  
 
 
 
ORGANISM STRAIN CHARACTERISTICS SOURCE 
Escherichia coli MM294-4 Nal-R , end A1, hsdR17 S. Quan  
E. coli GM2929-1 Rif-R, Dam- , Dcm-  E. Dabbs 
E. coli MM294-4   Nal-R , end A1, , 
hsdR17 lysogenised 
with phage   
E. Dabbs 
E. coli CSH116 mut D, (dna Q), (gpt-
lac)5, rpsL, Tn10 
E. Dabbs 
E. coli MM294-1 rpoB E. Dabbs 
Rhodococcus 
erythropolis 
ATCC 4277  E. Dabbs 
R. fascians DSM20669   E. Dabbs 
R. rhodochrous HS1  S. Anderson 
R. rhodochrous HS6  S. Anderson 
R. rhodochrous HS13  S. Anderson 
Gordonia 
rubropertincta 
ATCC 25593  E. Dabbs 
Bacillus subtilis 1 A3-1 Spc-R Antibiotic 
inactivation assay 
organism 
E. Dabbs 
Mycobacterium 
smegmatis 
Mc 2155  E. Dabbs 
Arthrobacter 
oxydans 
C7  E. Dabbs 
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Table 2: Plasmid vectors used in this work 
PLASMID CHARACTERISTICS SOURCE 
pDA71 E. coli-Rhodococcus shuttle 
vector 
E. Dabbs 
pUC18/19 E. coli cloning vector 
pBR322 ori, MCS in lacZ´, 
Amp-R 
Fermentas 
pGem T-Easy E. coli highly copy number 
vector, lac Z' gene, single 
3´ thymidine, overhangs, 
Sp6 and T7 promoters  
Promega 
pNV18 Nocardia-Rhodococcus 
shuttle vector 
Y. Mikami 
pACYC184 Cmp-R, Tet-R    E. Dabbs 
pDN1 Amp-R D. Ndwandwe 
pBA1  Kan-R  This work  
 
2.2 Media and growth conditions 
 
Luria-Bertani (LB) was used for the pre-culture of E. coli and other strains by 
inoculating the organism into 5 ml of the broth, E. coli MM294-4 was incubated at 
37°C while the  lysogen strain was incubated at 30°C. Rhodococcus and other Gram 
positive strains were incubated at 300C except Mycobacterium smegmatis which was 
incubated at 37°C.  
 
Grown cultures of E. coli were kept on the wheel at room temperature while those of 
the Gram positive strains were kept at 4°C for short term storage. Grown strains on 
agar plates were also kept at 4°C for short term storage while freshly grown strains 
were kept in 33% glycerol at -70°C for long term storage.  
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2.3 Determination of MIC due to pDN1 and pBA1 
 
Plates were prepared and dried overnight at 37°C. The plates contained 100 µg/ml Nal 
and 100 µg/ml Amp, plus different concentrations of the test antibiotics up to the 
concentration that would inhibit the growth of the clones in E. coli, while 100 µg/ml 
Kan was added to the plates for the Gram positive strains. The resistant clones to be 
used and the vector control were streaked on the LA Amp plates in order to obtain 
actively growing single colonies which were picked and re-suspended in 200 µl sterile 
distilled water, in the wells of the plate replicator. Preparation of different 
concentrations of antibiotics used is contained in appendix C on page 79.  
  
2.4 DNA preparations 
 
2.4.1 E. coli mini plasmid preparation 
 
This procedure was carried out using alkaline lysis method; single colonies of bacteria 
or a group of clones was inoculated in 1 ml of LB supplemented with 100 µg/ml Amp 
and was grown on the shaker at 37°C overnight. The cultures were transferred into 1.5 
ml Eppendorf tubes and harvested by spinning for 30s in micro-centrifuge to pellet 
the cells. The supernatant was discarded and the pellet re-suspended in 80 µl of 
solution I. 160 µl of solution II was then added and the contents mixed gently by the 
inversion of the tubes, they were then left to stand on the bench for 15 min or more at 
room temperature. 120 µl of solution III was added and the contents mixed vigorously 
by shaken, they were allowed to stand on ice for 5 min before centrifuging for 5 min 
at 10,000 rpm in the cold.  
 
The supernatant was gently removed, put into a sterile Eppendorf tube and warmed at 
42°C for 2 to 10 min. 220 µl of isopropanol was added and mixed gently by inversion; 
it was then allowed to stand at room temperature for 5 min. Precipitation of the DNA 
was carried out by centrifuging for 5 min at room temperature, the supernatant was 
discarded and the pellet washed with 150 µl of ethanol, mixed by gentle inversion and 
spun at room temperature for 1 min. The supernatant was discarded and carefully 
blotted on paper towel; the DNA was then dried in the speed-vacuum for 20 min. The 
dried pellet was re-suspended for 2 hr in 100 µl sterile distilled water. The 
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concentration of the DNA was checked by running 5 µl of the re-suspended DNA on 
0.8% agarose gel with the ladder marker. Appendix B on page 75 contains the recipes 
for various solutions used in this work.  
 
2.4.2 Rhodococcus mini plasmid preparation 
 
Bacteria cultures were inoculated into 300 µl of LBG (LB + 2% glycine) containing 
the appropriate antibiotic and grown at room temperature for 2-3 days. 200 µl of the 
culture was transferred into a sterile Eppendorf tube and microfuged for 1 min at the 
room temperature. The pellet was resuspended in 200 µl TE to which a 5 mg/ml 
lysozyme had been added, the suspension was then incubated at 370C for 1 hr. A 40 
µl volume of 5.0 M KAc (pH 6.0) was added, mixed vigorously, and left on ice for 5 
min. The content was microfuged for 5 min at 4°C and the supernatant was transferred 
into a sterile Eppendorf tube. Purification of the DNA was carried out by the phenol-
chloroform method, and the DNA was precipitated with 1.0 M NaCl and 96% ethanol. 
The plasmid DNA was then dried in the Speedvac for about 20 min and the pellet 
obtained was resuspended in 150 µl of sterile distilled water for 2 hr. 
 
2.4.3 Large scale plasmid DNA isolation 
 
The appropriate strain was inoculated into 100 ml LB supplemented with 100 µg/ml 
Amp and was grown overnight on the shaker at 37°C. The culture was harvested by 
pelleting in centrifuge in a JA 10 Beckman rotor at 6,000 rpm for 10 min. The cell 
pellet was re-suspended in 5 ml solution I in JA 20 tube. 10 ml of solution II was 
added and mixed gently by inverting the tube to lyse the cells; it was then incubated at 
room temperature for about 30 min. 7.5 ml of solution III was added to precipitate 
proteins, lipids and cell wall material, and the tube shaken vigorously for 15-20s. The 
tube was placed in ice/water slurry for 15 min and the precipitate removed by 
centrifuging in a pre-chilled JA 20 rotor for 10 min at 15,000 rpm. 
 
The supernatant was decanted into a fresh JA 20 Beckman centrifuge tube as the 
white pellet was discarded. The supernatant was warmed in 37°C water bath, 12 ml of 
isopropanol was added, and the tube was covered with parafilm, mixed gently by 
inversion and placed at room temperature for 15 min. The DNA was precipitated by 
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centrifuging in JA 20 rotor at room temperature for 10 min, 15,000 rpm. The pellet 
was washed with 2 ml 96% ethanol and re-centrifuged for 1 min at room temperature. 
The pellet was dried in the speed-vacuum for 20 min and re-suspended in 4 ml TE 
buffer for 2 hr with gentle agitation in a 300C water bath. 4.1g of CsCl was added and 
dissolved by gentle agitation, 400 µl of a 1% solution of EtBr was also added and the 
refractive index was adjusted to 1.387-1.389 using a refractometer. A Pasteur pipette 
was used to load the solution into a quick seal tube and sealed with heat. 
 
The solution was then placed in a vertical VTi 65.2 rotor and spun in an ultra-
centrifuge at 10°C, 45,000 rpm for 16 hr. Plasmid DNA was extracted (the lower band 
in the tube) with a hypodermic syringe and needle; this was then transferred into a 
sterile Eppendorf tube. 
 
2.4.4 Ethidium bromide removal 
 
Ethidium bromide was removed from the plasmid DNA by adding 150 µl of butanol 
into the tube, it was inverted several times to mix the contents and the butanol layer 
which appeared on top was removed with a Gilson pipette. This process was repeated 
until the ethidium bromide was not visible in the tube, usually about three to four 
times. The DNA was stored in CsCl at -20°C until needed. 
 
2.4.5 Precipitation of DNA 
 
A 100 µl of the DNA from the large scale isolation was measured and transferred into 
a sterile Eppendorf tube, twice this volume of sterile distilled water was added, more 
than two times the combined volume of ethanol was added  and the contents mixed by 
inversion. The DNA was recovered by spinning in a microfuge for 20 min at 4°C. The 
supernatant was gently decanted off and discarded while the tube was blotted on 
paper towel to remove excess liquid and then dried in the speed-vacuum for 20 min. 
The pellet was re-suspended in 200 µl of sterile distilled water. 
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2.4.6 Low gelling agarose electrophoresis 
 
 Plasmid DNA was digested with restriction enzyme(s) to release the band of interest; 
5 µl of tracking dye was added to it in the tube and loaded on 0.6% low gelling 
agarose. The gel electrophoresis tank containing 0.5× TBE was placed at 40C 
overnight before use. The voltage was set at 100V, the current at 20 amp and the 
DNA was allowed to run on the gel until the tracking dye almost migrated to the edge 
of the gel. The bands of interest on the gel were cut out while viewing under UV light 
at 366 nm wavelength using a sterile scalpel blade. 
 
2.4.7 DNA fragment purification  
 
DNA extraction could be done by melting the excised bands on gel at 60°C in the 
water bath or by the freeze squeeze method. The latter was employed in this work as 
the excised band of interest was chopped into pieces in the Eppendorf tube by a sterile 
spatula, the tube closed, wrapped in a plastic and frozen at -70°C for more than 30 
min. It was then thawed between 10-15 min and spun for 10 min at 4°C. The 
supernatant was extracted and transferred into a new sterile Eppendorf tube. 
 
2.4.8 Phenol-chloroform extraction 
 
For phenol-chloroform extraction to be carried out, the DNA recovered from CsCl2 
density gradient in the tube must be up to 300 µl. Phenol at a volume of 1/3 of the 
content was added to the DNA, gently mixed and spun in the microfuge for 5 min at 
4°C. The top layer was extracted and transferred into a sterile Eppendorf tube for the 
process to be repeated three times. Chloroform at a volume of 1/3 was then added to 
the DNA, mixed gently, and spun for 30s at room temperature. The top layer was then 
extracted and transferred into a sterile Eppendorf tube. 
 
2.4.9 Salt-ethanol precipitation 
 
One tenth volume of 1M sodium chloride was added to the DNA gently mixed and 
ethanol at two times the total volume of the content was added and mixed by inverting 
the tube. The precipitated DNA was recovered by spinning in the microfuge for 20 
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min at 4°C. The supernatant was decanted off and the DNA was dried in the speed-
vacuum for 20 min. The dried pellet was re-suspended in 50 µl of sterile distilled 
water and the DNA concentration was checked by running about 2 µl on a 0.8% 
agarose gel to determine the volume needed for ligation. 
 
2.5 DNA manipulations 
 
2.5.1 Restriction enzyme digestions 
 
Restriction enzymes were obtained as commercial products from New England 
Biolabs, Amersham, Promega or Boehringer Mannheim and the total volume of the 
mixture for digestions were kept at 15 µl. 13.5 µl of the DNA was transferred into a 
sterile Eppendorf tube to which 1.5 µl of 10× appropriate buffer was added and mixed 
gently, briefly spun and 0.5 µl of the enzyme then added to the tube, tapped briefly 
and microfuged for 1-2s followed by incubation at the required optimum temperature 
from the manufacturer’s guide. In order to carry out a double digestion, the guide 
from the manufacturer was followed to know the buffer best suited for both enzymes 
as well as the ratio of the enzymes and the required optimum activity temperature for 
incubation. Where no common buffer could be found, double digestions were done 
sequentially starting with the enzyme that required the lower salt. All restriction 
digestions were carried out for a minimum of 3 hr. A “no DNA” control was included 
to allow for comparison. 
 
2.5.1.1 Extraction of DNA from the AVS clone 
 
The resistant clone was inoculated into a 100 ml volume of LB supplemented with 
Amp at 100 µg/ml for a large scale DNA isolation. It was then grown on a shaker 
overnight at 37°C, the plasmid DNA was extracted, ethidium bromide was removed, 
and CsCl
 
gradient centrifugation was performed to purify the DNA. 
 
2.5.1.2 Extraction of erythromycin resistance insert  
 
The DNA was digested overnight with Hind III in order to separate the insert from the 
vector DNA. This was followed by 0.6% low gelling agarose electrophoresis. The 
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band on the agarose carrying the insert was excised with a sterile scapel on a trans-
illuminator, phenol-chloroform extraction was carried out and the DNA was 
precipitated using the salt-ethanol method. 
 
2.5.2 Ligation 
 
T4 DNA ligase from Boehringer Mannheim was used in this work to join the DNA 
with the vector at the required site(s) for the required library or in preparation for 
sequencing. The total ligation volume was kept at 20 µl and the ligation was 
performed at 22°C for 16-22 hr. 
2.5.3 Dephosphorylation 
 
This procedure was carried out after the vector to be used for ligation was treated with 
the restriction enzyme and incubated. This is to prevent it from re-ligating itself and 
denying the introduction of the insert. It acts by removing the 5´-phosphates that are 
required for ligation by DNA ligase however, not affecting its ligation to the insert 
that retains its own 5´-phosphates. Calf intestinal alkaline phosphatase from 
Boehringer Mannheim was used in this work. It was inactivated by phenol-chloroform 
extraction after an overnight incubation and the DNA was recovered by salt-ethanol 
precipitation method. 
 
2.6 Transformations 
 
2.6.1 E. coli calcium chloride transformation 
 
E. coli strain was inoculated into 5 ml LB supplemented with 100 µg/ml Nal and was 
grown on the wheel at 37°C overnight. 200 µl of this culture was added to pre-
warmed 20 ml LB supplemented with 0.5% glucose and grown with vigorous aeration 
on the shaker at 37°C until an O.D590 of 0.2-0.4 had been reached (within 1 hr 45 min 
to 2 hr). The cells were then placed in ice-water slurry for 5 min and then centrifuged 
for 5 min at 10,000 rpm in a pre-chilled JA 20 Beckman rotor. The supernatant was 
decanted off, the cells re-suspended in 10 ml transformation buffer and left on ice for 
15 min or more. The cells were centrifuged again for 5 min at 10,000 rpm, the 
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supernatant was discarded, the cells were gently re-suspended in 1.33 ml 
transformation buffer and left to stand on ice for 2-24 hr.                                                                                                  
 
The DNA to be used was placed on ice for more than 10 min and to each tube of 10 
µl, 50 µl of competent E. coli cells were added, tapped gently to mix and left on ice 
for 10 min to allow diffusion of the DNA into the host/recipient cells. The competent 
cells were heat shocked for 90s at 44°C to transform the DNA and 0.5 ml of LB was 
added to the tube(s). Incubation was carried out at 37°C for 1 hr to allow for 
phenotypic expression of antibiotic resistance, the cap(s) of the tube(s) were left 
opened during incubation. 
 
The transformed cells were then spread on plates that had been dried at 37°C for 24-
48 hr which contained 100 µg/ml Amp; chloramphenicol was also added when 
necessary. The plates were incubated overnight at 37°C. Competent cells only were 
also spread on the plate to serve as the control and vector only DNA also included 
during ligation.  
 
2.6.2 Electroporation 
 
Cultures of Rhodococcus and other Gram positive strains were inoculated into 5 ml 
LBSG with 2% glycine for 2 days at 30°C, the culture was then transferred into a 
sterile Eppendorf tube and spun for 1 min in a slow microfuge. The supernatant was 
discarded and 1 ml of sterile distilled water was added to wash the pellet, this process 
was repeated three times, a 100 µl volume of the cells was transferred into a sterile 
Eppendorf tube and about 1-10 µl of DNA was added. It was mixed by bubbling air 
through the mixture and allowed to stand for 5 min on the bench. 
 
Cells were transferred into a cuvette and tapped gently to make sure that the cells 
were evenly distributed. The outside of the cuvette was wiped to dry and placed in the 
white chamber of the Gene Pulser to electroporate the cells. The parameters under 
which the electroporation was carried out include; 25µF capacitance, 2.5kV voltage 
and 400 resistance. The time constant at which electroporation took place was 
recorded and LB was added to the cells immediately, it was then allowed to stand on 
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the bench for 10 min, followed by incubation on the shaker at 30 rpm (30°C) for 3 hr. 
Aliquot of the cells were then added onto the relevant antibiotic plates. 
 
2.7 Mutagenesis 
 
2.7.1 Spontaneous mutation 
 
The Mycobacterium smegmatis gst gene carried in plasmid pDN1 was transformed 
into E. coli MM294-4 strain using the calcium chloride method and into Rhodococcus 
by electroporation. The transformants containing the insert were inoculated into 5 ml 
LB + 100 µg/ml Nal to select for the growth of E. coli, 100 µg/ml Amp was added to 
maintain the plasmid in the Gram negative strain, while 100 µg/ml Kan was added to 
maintain the plasmid in the Gram positive strains. A 100 µl volume of the pre-culture 
was spread on LA Amp plates as well as LA Kan plates at high concentrations of the 
test antibiotic(s). The plates were incubated at 37°C and 30°C for E. coli and the 
Rhodococcus strains respectively. Colonies were found after 2 days in E. coli and 
after 4 days in Rhodococcus.  
 
2.7.2 Chemical mutagenesis (EMS) 
 
Strains carrying the insert were grown in 5 ml LB with 100 µg/ml Nal + 100 µg/ml 
Amp,   and 5 ml LB + 100 µg/ml Kan up to O. D. 0.2-0.4 (590nm) in E. coli and 
Rhodococcus strains respectively. A 100 fold dilution was made from the overnight 
culture in LB and grown in the flasks on the shaker at 37°C and 30°C for about 4 hr 
and overnight. 1 ml of the 100 fold diluted culture was transferred into a sterile 
Eppendorf tube and microfuged for 30s, the pellet obtained was washed with 1 ml 
buffer E (pH 5.0). 2% v/v of the mutagen was dissolved in the buffer and 0.5 ml 
volume of this was added to the cells that had been resuspended in 0.5 ml of the 
buffer to a 1 ml volume. 
 
The content was incubated at 37°C in a pre-set water bath for 1 hr. The mutagen was 
removed by spinning down in the microfuge for 30s and the cells washed with buffer 
E twice to stop the reaction. The cells were dissolved with LB and added to the tube 
containing 5 ml LB + 100 µg/ml Nal and 100 µg/ml Amp, and 5 ml LB + 100 µg/ml 
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Kan. They were then incubated at 37°C and 30°C overnight and a 100 µl of the 
mutagenized cells were then spread on selective plates. 
 
2.7.3 Marker Rescue 
 
It was necessary to verify that the mutations obtained from both the spontaneous 
selection and after chemical mutagenesis were plasmid borne, and to ascertain this the 
pools of colonies found on different selective plates were washed off with 2-3 ml LB 
into a McCartney bottle and the content briefly vortexed to have a homogenous 
mixture. 100 µg/ml Amp was added into each bottle and grown for 4 hr on the shaker 
at 37°C. Plasmid DNA extraction was carried out on the grown cultures according to 
alkaline lysis method. The DNA obtained from the mini prep was used to transform  
E. coli MM294-4 strain via calcium chloride transformation method and cells were 
spread on selective plates in which the same concentration of the test antibiotic(s) that 
was used for the mutagenesis had been added, ampicillin was also added to maintain 
the plasmid. 
 
2.7.4 Plasmid curing  
 
This procedure was carried out in order to remove the plasmid from the E. coli strain 
used for transformation to verify whether the mutation was carried on the plasmid in 
the clone obtained from mutation, or as a result of changes in the chromosomal DNA 
of E. coli.                                                                                           
 
A colony was inoculated into 5 ml LB and was grown to stationary phase at 37°C 
overnight. A 1000 fold dilution was carried out on the culture and grown on the wheel 
at 37°C overnight again. This procedure was repeated for 5 days to obtain a ~50 
generation from the dilutions at which stage the strain should have lost the plasmid. 
Serial dilutions were made from the culture obtained after the fifth day up to 10-9 and 
100 µl of the dilutions plated on LA Nal. Single colonies were picked from these 
plates and were patched unto LA + Cmp, LA and LA Amp plates. Pre-cultures of the 
strain from the different plates were made by inoculating into 5 ml LB and grown on 
the wheel at 37°C overnight; these were used for transformation with the pool of DNA 
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obtained from spontaneous mutation, while the parental DNA was also included as 
the control. 
 
2.7.5 Error prone PCR (epPCR)  
 
The sequenced oligonucleotide from Fermentas was used as the template and epPCR 
was used to introduce random point mutations into the rgt ORF. This was achieved by 
adding a 0.5mM concentration of MnCl2 and increasing the concentration of the 
MgCl2 (10mM) in the reaction mixture. The increased concentration is usually of 
insignificant impact on the level of amplification obtained from the PCR.  
 
M13/pUC sequencing primer (-20), 17-mer from Fernentas was used with 5´-d 
(GTAAAACGACGGCCAGT)-3´ and 5´-d (CAGGAAACAGCTATGAC)-3´ as the 
forward and reverse primers respectively. The reaction mixture was carried out in a     
thin-walled PCR tube and it was amplified by using a MJ MINI TM personal 
thermocycler supplied by Biorad. The following tables show the composition of the 
components used and the amplification parameters under which cycling was carried 
out; 
 
Table 3a: Table showing the reaction mixture for error prone PCR  
Component Final 
concentration 
Control vol ( Component vol for 
50µl mixture (µl) 
Water, Nuclease 
free 
- 30.75  28.5  
10× Taq buffer 1× 5  5  
2 mM dNTP mix 0.2 mM each 5  5  
Forward primer 0.5 µM 2.5 2.5 
Reverse primer 0.5 µM 2.5 2.5 
Taq DNA 
polymerase 
1.25 units 0.25 0.25  
25 mM MgCl2 2.0 mM 4  4  
Template DNA 0.1 µg - 2.25 
  50  50  
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Table 3b: Table showing the cycling conditions for the error prone PCR 
Cycle Temperature (°C ) Time (minute) 
First:     Initial 
Denaturation  
               (DNA Template) 
 
95 
 
10 
 
Second:  Denaturation 
 
               Annealing 
                
               Extension 
 
95 
 
45 
 
72 
 
2 
 
2 
 
4 
 
Third:  Final extension 
 
 
72 
 
 
10 
 
 
The second cycle was repeated 25 times to generate the amplification of ~1.8 Kb rgt 
gene region. The PCR product was then analyzed on a 1.2% agarose gel 
electrophoresis to verify the amplification of the fragment of interest. Thereafter, the 
product was digested and run on a 0.6% low gelling agarose gel electrophoresis to 
separate the fragment. The DNA was excised from the gel with a sterilized scalpel 
while viewing under UV light at 366 nm and the DNA was extracted by phenol-
chloroform method, followed by salt-ethanol precipitation, re-suspended in sterile 
distilled water and ligated into pDA71 for transformation in E. coli MM294-4 for post 
amplification analyses.  
 
2.8 Plate assays of antibiotic inactivation  
 
2.8.1 Antibiotics concentration calibration  
 
Prior to the inactivation assay experiments, antibiotics to be tested for inactivation 
assay were calibrated on the plates in order to determine the concentration of the 
antibiotic that will give the required zone of inhibition. Different concentrations of 
antibiotics were added to 5 ml LB in the test tube and were incubated on the wheel at 
37°C overnight. A 100 µl of assay organism was spread on the plate and agar plugs 
were removed by the sterile end of a Pasteur pipette. A 70 µl volume of the different 
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concentrations of antibiotics were added to the holes, incubated at 4°C for 4 hr to 
allow diffusion and was later incubated at 37°C overnight. 
 
Zones of inhibition were measured, calibration curve was drawn and the best 
concentration at which the assay was to be carried out was determined, this 
concentration was made use of in all the inactivation assay experiments carried out.  
 
2.8.2 In vivo inactivation 
 
E. coli cultures containing plasmid pDN1 gst gene was grown in 5 ml LB overnight at 
37°C on the wheel. The overnight culture was diluted 100 fold and grown for 4 hr in 
LB on the shaker at 37°C, the cells were then challenged with the test antibiotic at a 
concentration of 20 µg/ml and grown overnight at 37°C. Bacillus subtilis 1 A3-1 and      
E. coli MM294-4 strains were used as the assay organisms. They were diluted 1:100 
and spread on LA ½ agar plates (the plates contain half of the normal agar) + 200 
µg/ml Spc/Str. Agar plugs were removed by the sterile end of a Pasteur pipette and 70 
µl of the challenged culture(s) poured into each well. It was incubated for 4 hr in the 
cold room to allow diffusion, followed by an overnight incubation at 37°C. Diameters 
of zones of inhibition found on the plate(s) were measured and recorded.  
 
2.8.3 In vitro inactivation 
 
Clones were grown in 10 ml LB with 100 µg/ml Nal and 100µg/ml Amp + the test 
antibiotic(s) in a flask on the shaker at 37°C overnight. The cultures were centrifuged 
at 15,000 rpm in a JA 20 Beckman rotor for 5 min to pellet the cells. The cells were 
washed with sonication buffer twice to remove the antibiotic. This was followed by 
the extraction of crude cells by sonication for 10s in ice about 3 or 4 times and spun 
down in the microfuge at 4°C. The clarified supernatant was transferred into a sterile 
Eppendorf tube where antibiotic with the appropriate co-factor were added, this was 
then followed by incubation at 37°C overnight. 
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The reaction mixture with the following constituents was used: 
 
    Vol (µl) 
Sonication buffer            31.5 
Antibiotic (Cmp) 4 mg/ml      1.5 
Acetyl-CoA 40mM                15 
Magnesium acetate 2mM      15 
Glutathione 80mM                7.5 
LDR 1 µg/ml each                  6 
Cell homogenate                    58.5 
Total                                      135 
 
The reaction was stopped after the incubation period with the enzyme proteinase K 
(300 µg/ml) and boiled at 56°C for 15 min. The assay organism was diluted 1:100 and 
spread on the LA half agar plate + 200 µg/ml Spc/Str. Agar plugs were removed by 
the sterile end of a Pasteur pipette and 70 µl of the reaction mixture was added to the 
wells. The plate was incubated for 4 hr at 4°C to allow diffusion; this was then 
followed by an overnight incubation at 37°C. Diameters of the zones of inhibition 
were measured and compared with the control. 
 
2.9 Automated DNA sequencing 
 
2.9.1 Preparation of DNA for sequencing    
 
GFX micro plasmid prep kit from Amersham Biosciences was used to prepare the 
DNA for sequencing. The protocol is an improved alkaline lysis procedure for the 
purification of DNA as outlined in the instruction manual (2004). A 2 ml volume of 
an overnight culture was prepared using the clone from the transformation plate. 
 
Cell lysis was carried out by transferring 1 ml of the culture into a 1.5 ml microfuge 
tube. It was then spun for 30s to harvest the cells. Supernatant was removed by 
aspiration without disturbing the cell pellet and was re-suspended in 150 µl of 
solution I with vigorous vortexing. 150 µl of solution II was added and mixed by 
inverting the tube 15 times. A 300 µl volume of solution III was added at the soonest 
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time possible and mixed by inverting the tube until a flocculent precipitate appeared, 
this was continued until the precipitate was evenly dispersed. It was important for the 
precipitate to be broken up effectively to ensure consistent yield, the mixing was 
however done gently in order not to share genomic DNA with the plasmid DNA and 
co-purify them. The content was centrifuged for 5 min at room temperature to pellet 
debris and one GFX column for each prep was prepared while centrifuging by placing 
the column in a collection tube. 
 
The supernatant was transferred to the prepared GFX column and it was incubated for 
1 min at room temperature, followed by spinning for 30s. The flow through was 
discarded by emptying the collection tube and 400 µl of wash buffer was added to the 
column. The buffer was removed by centrifuging for 1 min at room temperature and 
the matrix dried prior to elution. The GFX column was transferred to a fresh 
Eppendorf tube and a 100 µl volume of TE buffer was added directly to the top of the 
glass fiber matrix in the GFX column. The sample was incubated for 1 min at room 
temperature, and then centrifuged for 1 min to recover the purified DNA. 
 
2.9.2 Spectrophotometric Analysis  
 
Concentration of the plasmid DNA extracted from the mini prep was checked on the 
Nano drop Spectrometer, supplied by Inqaba Biotec in preparation for sequencing. A 
concentration of 10 ng/µl was needed for 100-500 bp, and 20 ng/µl for 500 - 1000 bp, 
an additional 100 ng/µl was needed for every additional 500 bp of plasmid DNA up to 
5 Kb. The DNA was diluted by sterile distilled water until the required concentration 
was achieved. It was then sent to Inqaba Biotec for automated sequencing.                                                                                                                
 
2.9.3 Sequencing Analysis 
  
Bioinformatics programmes were used to analyze the results obtained from the 
sequencing analysis by converting the result from Inqaba into nucleotides with the 
fasta format. The data were then analyzed using the following web addresses: 
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 Table 4: Website addresses of the sequence analysis programs 
Program Web Site 
FASTA http://www.ebi.ac.uk 
BLAST Http://www.ncbi.nlm.nih.gov/BLAST 
WEBCUTTER http://www.ccsi.com/cgi-bin/firstmarket/cutup 
ExPASy http://www.expasy.org 
GENEMARK http://genemark.biology.gatech.edu/GENEMARK/webgenemark.html 
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Chapter 3 
 
 
RESULTS AND DISCUSSION 
 
 
3.1 Expression of GST gene in E. coli 
 
Plasmid pDN1 was prepared by Duduzile Ndwandwe. She isolated the gst gene from 
Mycobacterium smegmatis mc2155 strain and amplified it by the polymerase chain 
reaction method. The primers she constructed contain: 5  ´
GTGATGGCTCAGGGCACCTACGTC 3  ´ for the forward reaction, and 5  ´
TCAGCCCGCGCCGTGACCGGCG 3  ´ for the reverse reaction. The 1000 bp size 
DNA fragment was excised, purified and cloned into pUC18 vector. It was sent for 
sequencing, and the sequence analysis confirmed glutathione S-transferase gene (D. 
Ndwandwe, personal communication).  
 
3.2.1 Determination of MIC with respect to pDN1 in E. coli 
 
To determine the minimum inhibitory concentrations (MICs) conferred by pDN1, 
actively growing cells were used for spot tests. This was carried out at an increasing 
concentration of chloramphenicol, kanamycin, kasugamycin, erythromycin, 
tetracycline, spectinomycin, streptomycin, and fusidic acid in E. coli MM294-4 strain 
on LA plates, and E. coli MM294-1 strain was used for Nalidixic acid because of its 
resistance to MM294-4 strain, shuttle vector pDA71 was used for the cloning of 
pDN1 and therefore was necessary to be included in this experiment as the vector 
control. The plates were supplemented with 100 µg/ml Amp + 100 µg/ml Nal (except 
the plate where Nal was tested), and were incubated at 37°C for 24 hr and 48 hr 
respectively. The MIC increase was < 2 fold for most of the antibiotics tested but for 
Kan which showed a 3 fold increase, and no significant difference was detected 
between the plates incubated for 24 hr and those of 48 hr. The results obtained after 
carrying out the experiment five times are shown in figures 3a and 3b.  
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Fig. 3a and b: MICs due to pDN1 in E. coli MM294-4 and 294-1 strains at 37°C. 
Control without gst gene: pDA71  
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3.2.2 MIC of pDN1 with respect to tetracycline and its derivatives 
 
Spot tests were further carried out on the strain E. coli MM294-4 transformed with 
pDN1 for expression of resistance to tetracycline and its derivatives: chlortetracycline 
(chlortet) and oxytetracycline (oxytet). The plates were again incubated for 24 hr and 
48 hr. The results showed that the resistance observed to tetracycline was not due to 
its derivatives with the highest MIC at 2µg/ml in chlortetracycline after 24 hr, and no 
growth was found in oxytetracycline even after a 48 hr incubation period. 
 
The MIC of tetracycline was slightly higher than the vector control and the result after 
48 hr of incubation showed that the best MIC in tetracycline is at 5 µg/ml 
concentration  as manifested by secondary mutant at 6 µg/ml after a 48 hr incubation 
period. 
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Fig. 4: MIC of pDN1 with respect to tetracycline and its derivatives 
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3.2.3. Phenotypic characterization of M. smegmatis chloramphenicol resistant 
clone 
 
Spot tests for chloramphenicol resistance were carried out on LA plate and the plates 
enriched with 0.5% glucose (LA(Glu), 80% phosphate buffer (L(A-N), and 0.5% 
glucose + 80% phosphate buffer (L(A-N)Glu). Effect of temperature on the growth of 
the clone in those media was also tested by incubating the plates at varying degrees of 
temperature i.e. 24°C, 37°C and 42°C. The result showed a < 2 fold MIC increase in 
all the media used and there was no noticeable difference on the growth at 24°C and 
37°C. The best MIC differences were observed on L(A-N) plates at 42°C where the 
clone conferred the highest resistance to the test antibiotic. A slight increase in MIC 
was also noticeable on the L(A-N)Glu plate at this temperature compared with the 
other plates, hence it could be concluded that LA supplemented with phosphate buffer 
at 42°C gave the best phenotypic expression of the clone in E. coli. 
 
0
1
2
3
4
5
6
7
8
LA LA(Glu) L(A-N) L(A-N)Glu
Ch
lo
ra
m
ph
en
ic
o
l c
o
n
ce
n
tr
at
io
n
 
(ug
/m
l)
pDN1
pGem
 
Fig. 5: Effect of different rich media compositions on chloramphenicol resistance 
phenotype in E. coli MM294-4 at 24°C 
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Fig. 6: Effect of different rich media compositions on chloramphenicol resistance 
phenotype in E. coli MM294-4 at 37°C 
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Fig. 7: Effect of different rich media compositions on chloramphenicol resistance 
phenotype in E. coli MM294-4 at 42°C   
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3.3 Expression of gst in the Gram positive background 
 
To investigate the expression of the M. smegmatis mc2155 gst gene in the Gram 
positive background, this gene was ligated into pNV18 shuttle vector via the PstI and 
SphI sites. The construct, termed pBA1, was electroporated into Gram positive 
bacteria: Rhodococcus sp., Mycobacterium sp., Gordonia sp. and Arthrobacter sp. 
Time constants were recorded, cells were spread on LA supplemented with 100 µg/ml 
Kan and incubated at 30°C.  Growth was observed on the plates after 3 days, some 
plates gave a very small number of colonies while there was no growth on others. The 
experiment was reapeated three times to ensure its accuracy.  The incubation period 
was increased for up to 10 days in order to obtain growth on the plates where there 
were no growth since all the conditions necessary for the uptake of DNA in the srains 
have been observed, yet no colonies were found.  
 
The results obtained from the electroporation showed that only pBA1 transformants in 
strains Rhodococcus erythropolis ATCC 4277 and Rhodococcus rhodochrous HS1, 
HS6 and HS13 could be used for further experiments, this is because there were too 
little number of colonies in Mycobacterium  smegmatis and Rhodococcus fascians 
strains and no growth at all in Arthrobacter oxydans and Gordonia rubropertincta 
strains. Results are presented in table 5. 
 
Table 5: Electroporation of pBA1 into the Gram positive strains  
Organism Strain No. of 
colonies 
Mycobacterium smegmatis mc2155 7 
Rhodococcus fascians DSM20669 14 
Rhodococcus erythropolis ATCC 4277 Confluent 
growth 
Rhodococcus rhodochrous HS1 Confluent 
growth 
Rhodococcus rhodochrous HS6 Confluent 
growth 
Rhodococcus rhodochrous HS13 Confluent 
growth 
Arthrobacter oxydans C7 0 
Gordonia rubropertincta 
 
25593 0 
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3.4 Antibiotic MICs conferred by pBA1 in the Gram positive background 
 
Spot tests were carried out on LA + Kan 100 µg/ml plates with  increasing 
concentrations of the test antibiotics using the clones obtained from the 
electroporation of Rhodococcus rhodochrous strains HS1, HS6, HS13 and R. 
erythropolis ATCC 4277.                     
 
R. rhodochrous HS strains were considered for this experiments because of their 
susceptiblity to a wide range of antibiotics and as such, any noticeable increase in 
MIC could be deemed to have occurred as a result of the presence of the gst gene in 
the clone. Several classes of antibiotics were tested on the clone which include: 
macrolides, aminoglycosides, -lactam, quinolone, tetracycline and  chloramphenicol. 
 
3.4.1 MIC of pBA1 in Rhodococcus rhodochrous HS1  
 
Resistance to chloramphenicol and the aminoglycosides  kasugamycin, spectinomycin 
and streptomycin was investigated in R. rhodochrous HS1. Other antibiotics tested 
include, nalidixic acid, rifampicin, ampicillin and erythromycin. Changes of 
resistance in this strain were found to be very low as the highest increase in MIC 
obtained was 3× with respect to rifampicin. There was a 2 fold increase in resistance 
to chloramphenicol and a 3 fold increase in ampicillin resistance. MIC increases to the 
other antibiotics tested were < 2 fold in this strain, and it could therefore be concluded 
that the expression of the gene was generally poor in the strain HS1.  
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Fig. 8a: Antibiotic MICs conferred by pBA1 in R. rhodochrous HS1:pNV18 
Vector control (Micrograms concentrations) 
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Fig. 8b: Antibiotic MICs conferred by pBA1 in R. rhodochrous HS1:pNV18 
vector control (Nanograms concentrations) 
 
 
 
 
 45 
3.4.2 MIC of pBA1 in Rhodococcus rhodochrous HS6  
 
Following tranformation of pBA1 into this Rhodococcus strain, spot tests were carried 
out to determine the MIC of different classes of antibiotics in this strain. There was a 
2 fold increase in MIC in chloramphenicol at 4 µg/ml concentration. The class 
aminogycosides as represented by streptomycin and spectinomycin also gave the 
same level of increase in resistance, except kasugamycin where a very slight increase 
in MIC was observed at 1600 ng/ml concentration. A slight increase in MIC of < 2 
fold was found in ampicillin and erythromycin but increase in resistance was not 
found in nalidixic acid. The very low MIC for kasugamycin was not surprising 
because it has always shown a weaker activity in the class aminoglycoside antibiotics 
used in this work. The folowing histograms (Fig.9a and 9b) show the results of MICs 
obtained in the strain HS6.   
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Fig. 9a: MICs conferred by pBA1 in R. rhodochrous HS6 (Micrograms 
concentrations) 
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Fig. 9b: Antibiotic MICs conferred by pBA1 in R. rhodochrous HS6 (Nanograms 
concentrations) 
 
3.4.3 MIC with respect to pBA1 in Rhodococcus rhodochrous HS13 
 
Investigation of the level of resistance conferred on the antibiotics used for MIC in 
HS1 and  HS6 strains was also carried out in HS13 strain. Spot tests were carried out 
using actively growing colonies obtained from the transformation in to this strain of 
Rhodococcus. The level of resistance obtained was similar to the one obtained for 
HS6, except for the fact that resistance to the antibiotics was higher in this strain. For 
instance, the resistance in streptomycin was up to 100 µg/ml and it was also higher in 
kasugamycin at 1,800 ng/ml although these were < 2× increase. 
 
A major difference was found in the MIC of  nalidixic acid which had the same level 
of  increase in MIC with the vector in HS6, but showed a 2 fold increase in MIC in 
HS13 at 20 µg/ml concentration. Ampicillin also gave a 2× increase in resistance in 
HS13 but at a much higher concentration compared with what was obtained in HS6, 
while chloramphenicol showed a less increase in resistance in this strain, but at a 
higher concentration of 8 µg/ml. Results of the MICs of HS13 are presented in the 
histograms (Fig. 10a and 10b) that follow.  
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Fig. 10a: MICs conferred by pBA1 in R. rhodochrous HS13 (Micrograms 
concentrations) 
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Fig. 10b: MICs conferred by pBA1 in R. rhodochrous HS13 (Nanograms 
concentrations) 
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3.4.4 MIC of pBA1 in Rhodococcus erythropolis  ATCC 4277  
 
Transformants of pBA1 into R. erythropolis ATCC 4277 were also tested. Results 
obtained showed that of all the strains in which the gst gene from M. smegmatis 
mc2155 strain was expressed, the best phenotypic differences were obtained in this 
organism. Levels of resistance conferred on different classes of antibiotics were up to 
5× increased MIC for spectinomycin at 20 µg/ml pBA1 and 4 µg/ml vector control, 
approximately 5× increased MIC for streptomycin at 14 µg/ml pBA1 and 3 µg/ml 
vector control and 5× increase for nalidixic acid at 10 µg/ml pBA1 and 2 µg/ml vector 
control. A 4 fold increase to 8 µg/ml was obtained for chloramphenicol, the principal 
antibiotic in this work, it was also a 4× increase for kasugamycin while < 3× increase 
was found for erythromycin.  
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Fig. 11a: MICs conferred by pBA1 in R. erythropolis ATCC 4277 (Micrograms 
concentrations) 
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Fig. 11b: Antibiotic MICs conferred by pBA1 in R. erythropolis ATCC 4277 
(Nanograms concentrations)  
  
0
100
200
300
400
500
600
700
800
900
Ksg
Antibiotic
Co
n
ce
n
tr
at
io
n
 
(u
g/
m
l)
pBA1
pNV18
 
 Fig. 11c: Kasugamycin MIC of R. erythropolis ATCC 4277 conferred by pBA1 
 
From the results of the the MICs of the gst gene, it could be deduced that the presence 
of the gene confers increased resistance to a wide range of antibiotics compared to the 
MICs obtained in the control without gst gene in figures 3a and 3b above. Also it was 
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found that the highest increase in MIC of chloramphenicol in the R. rhodochrous HS 
strains was at 2 fold in HS1 and HS6 while it was < 2× increase in HS13.  
 
The highest MIC increase in HS strains was at 3× increase in the antibiotic rifampicin 
while increase in MIC of the gst gene was very distinct in R. erythropolis ATCC 4277 
where up to 5× increase was obtained in the antibiotics spectinomycin and nalidixic 
acid, 4× increase in chloramphenicol and kasugamycin, 3× increase in streptomycin, 
and 2× increase in erythromycin. Therefore, the best increase in MIC of the gst gene 
was obtained in R. erythropolis ATCC 4277. 
 
3.5 Analysis of the Ery-R Gram positive DNA expressed in E. coli 
 
Analysis of the libraries containing the erythromycin resistant clones is the other 
major component of my Master’ s work. Erythromycin is produced by the 
actinomycete bacterium  Saccharopolyspora erythraea. It is a macrocyclic compound 
that contains a 14-membered lactone ring with two deoxy sugars attached. It inhibits 
replication by binding to the 50S subunit of the bacterial 70S rRNA complex and 
interferes with protein synthesis. 
 
The set of experiments involved in this part of my research work was to expand on 
heterologous expression of Gram positive DNA in the Gram negative background. 
Gram positive libraries carried by shuttle vector pDA71 which were maintained in    
E. coli were screened (Nteo M. D., MTech, 2006), and clones in many libraries were 
identified. Out of the 23 screened, ery-R  clones were found in 9. I carried out further 
analysis on 6 of these. These six clones from the ery-R libraries include: RX, K24, 
MP15, IP6, MCX and AVS. Three of the clones, MP15, MCX and AVS gave the 
highest MIC to erythromycin and two of these (AVS and MCX) were further tested 
on azithromycin. 
 
3.6.1 MIC of  ery-R clones in E. coli 
 
Since it was reported that the clones were resistant to erythromycin after their 
screening, I first confirmed this. The DNA from the afore-mentioned clones were 
transformed into   E. coli MM294-4 and the transformants obtained were used to carry 
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out spot tests in the antibiotic erythromycin. Colonies picked from the transformation 
plate were spotted on to LA plates supplemented with Amp at 100 µg/ml with the 
increasing concentrations of erythromycin up to 300 µg/ml. Plates were incubated at 
37°C and  the plates were allowed to grow for 24 hr as well as 48 hr together with the 
pDA71 vector control. 
 
The MICs were obtained at 100 µg/ml concentration of the antibiotic which gave a 2× 
increase in 3 of the 6 clones; MP15, MCX and AVS. There was no significant 
difference between the growth of the clones after 24 hr compared to the growth after 
48 hr, it was therefore concluded that the MIC was best at 100 µg/ml.  Figure 12 
shows the levels of resistance of 6 clones to erythromycin. 
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Fig. 12: MIC of selected Ery-R clones and pDA71 in E. coli 
 
3.6.2 MIC of Ery-R clones in pUC 18 
 
Two of the three clones that conferred the highest resistance on erythromycin were 
investigated further by ligating their DNA into pUC18, a high copy number vector 
because the MIC increase in vector pDA71 was modest. Transformants were again 
obtained in the E. coli MM294-4 strain and these were used to carry out spot tests on 
LA plates supplemented with Amp at 100 µg/ml with an increasing concentration of 
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erythromycin. Almost the same result was found in the pUC18 vector as obtained in 
pDA71 vector with the highest resistance to erythromycin at 100 µg/ml but slightly   
> 2 fold increase resistance as shown in Fig 13.   
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Fig. 13: MIC of Ery-R clones in E. coli using pUC18 Vector 
 
3.6.3 Azithromycin MIC of  Ery-R clones  
 
Further experiment was carried out on clones MCX and AVS to investigate their 
levels of resistance in another member of the macrolide class of antibiotic, 
azithromycin. This macrolide was developed for better stability and a broad spectrum 
action. It differs chemically from erythromycin by incorporating a methyl-sustituted 
nitrogen atom into the macrocyclic compound to make it a 15-membered lactone ring. 
It binds to the 50S subunit of the bacterial ribosome to inhibit translation of the 
mRNA thus interfering with the protein synthesis.                               
 
This experiment was carried out to determine which of the clones had resistance to 
more than one member of the macrolide class. Spot tests were carried out on LA 
plates supplemented with Amp at 100 µg/ml at an increasing concentration of 
azithromycin up to 10 µg/ml. AVS showed a higher resistance in this antibiotic with a 
5 fold increase resistance while the level of resistance in MCX was 3 fold. This result 
 53 
was an indication that AVS has a higher level of resistance to the class of macrolide,  
it was therefore chosen for further experiments. Figure 14 shows the results obtained.  
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Fig. 14: Azithromycin MIC conferred by Ery-R clones in E. coli 
 
3.7 Restriction digestions of the DNA from AVS 
 
Several restriction enzymes were used to carry out single and double digestions on the 
DNA. This was to construct a restriction map by finding the number of sites and their 
sizes in the insert. Sizes were calculated by using the standard curves generated from 
the distances migrated by the known molecular weight size markers run on the same 
gel, Gene Ruler Ladder Plus from Fermentas was used. The digestion was carried out 
overnight and run on 0.8% agarose. The number of sites obtained from the enzymes 
used are presented in table 6 as follows; 
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Table 6: Restriction digestions of DNA from AVS 
ENZYME 
 
NUMBER OF SITES 
NsiI 1 
Bam HI 0 
NarI 2 
AccI 2 
TaqI Numerous 
Sau3A Numerous 
Eco RI 0 
StuI 0 
NaeI 1 
NruI 1 
SmaI 0 
XhoI 1 
SalI 1 
 
3.7.4: Restriction map of AVS 
 
From the series of digestions carried out, it was found that NsiI and NruI were cutting 
the insert once and these were used to construct the restriction map. The other 
enzymes; SalI, XhoI and NaeI that cut once were found cutting very close to the 
HindIII ends of the insert, and from these results the restriction map was constructed 
as shown in figure 15 below. 
 
Hind III             NruI                                                     Nsi1                     Hind III 
 
             450bp                              1150bp                                    500bp            
 
Fig. 15: Preliminary restriction map of AVS 
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3.7.5 Sequencing of the ery-R DNA  
 
The approximately 1.2Kb insert (NsiI - NruI fragment) from AVS was ligated into 
pUC18 and transformed into the E. coli strain MM294-4. DNA from the 
transformants was purified using the plasmid prep kit from Amersham and the 
concentration of the DNA checked on the Nanodrop. The DNA obtained from this 
preparation was sent to Inqaba Biotec for sequencing, and the following nucleotide 
sequence was obtained. 
gccatacgggtgtacgcaaaatggtggataaaaacgcattaagtctg 
tggatgcsagaacgtagcgatctttgggtgcagccaaaagttgatggcgttgcggtaacc 
ctggtttatcgggacgggaaactgaacaaagcaatcagtcgcggtaatggcctgaaaggc 
gaggactggacgcagaaagttagcttaatttccgctgtgccgcaaaccgttagcgggcct 
ttagccaacagtacgcttcagggggaaatatttctccagcgcgaggggcatatccaacaa 
caaatggggggaataaatgcccgcgcaaaagttgctggcttgatgatgcgccaggacgat 
agcgacacgctgaattctctgggcgtttttgtctgggcatggccggatggaccgcagtta 
atgtctgatcgtttaaaagagctggctaccgcaggttttactctaacgcagacgtatacc 
cgtgcggtgaaaaatgctgatgaagttgcgcgcgtacgcaatgagtggtggaaagcggaa 
ttacccttcgtcaccgatggcgtagttgtacgagcggcgaaagagccagaatcccgccat 
tggctaccgggccaggcagagtggctggtggcctggaaatatcaacctgtagctcaggtt 
gccgaagtgaaggcaattcagtttgcggtgggtaagagcggtaaaatatcggtggttgcg 
tcactcgcacctgtcatgctggatgataaaaaagtccagcgggtgaatattggttccgtc 
aggcgctggcaggagtgggatattgcgcctggtgatcagattctcgtcagccttgccggt 
caggtatt 
Fig. 16: DNA sequence of AVS insert 
 
3.7.6 Nucleotide alignment of the AVS sequence 
 
Nucleotide alignment was carried out using BLASTN search for the 1150bp NsiI – 
NruI fragment. In this search, the zero e-value indicates the most significant 
alignment. It was most surprising that the nucleotide blast result showed it was an E. 
coli K12 DNA ligase, NAD (+) –dependent suggesting that contaminating E. coli 
DNA could have been cloned into the vector during library construction. Further 
investigation on the clone AVS was therefore discontinued but the results are 
summarized below. 
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Table 7: BLASTN nucleotide alignment search result 
Accession Description 
Max 
score 
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
CP000948.1 
Escherichia coli str. K12 
substr. DH10B, complete 
genome 
1496 1496 99% 0.0 99% 
CP000946.1 
Escherichia coli ATCC 
8739, complete genome 
1496 1496 99% 0.0 99% 
CP000802.1 
Escherichia coli HS, 
complete genome 
1496 1496 99% 0.0 99% 
AP009048.1 
Escherichia coli str. K12 
substr. W3110 DNA, 
complete genome 
1496 1496 99% 0.0 99% 
U00096.2 
Escherichia coli str. K-12 
substr. MG1655, complete 
genome 
1496 1496 99% 0.0 99% 
L10328.1 
E. coli; the region from 81.5 
to 84.5 minutes 
 
1496 1496 99% 0.0 99% 
 
 
 
gb|CP000948.1|  Escherichia coli str. K12 substr. DH10B, 
complete genome 
Length=4686137 
Features in this part of subject sequence: 
   DNA ligase, NAD(+)-dependent 
 Score = 1496 bits (1658), Expect = 0.0 
 Identities = 833/835 (99%), Gaps = 1/835 (0%) 
 Strand=Plus/Minus 
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Query2        
CCATACGGGTGTACGCAAAATGGTGGATAAAAACGCATTAAGTCTGTGGATGCSAGAACG  61 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
CCATACGGGTGTACGCAAAATGGTGGATAAAAACGCATTAAGTCTGTGGATGCGAGAACG  3916425 
Sbjct3916484 
Query62       
TAGCGATCTTTGGGTGCAGCCAAAAGTTGATGGCGTTGCGGTAACCCTGGTTTATCGGGA 12      
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TAGCGATCTTTGGGTGCAGCCAAAAGTTGATGGCGTTGCGGTAACCCTGGTTTATCGGGA  3916365 
Sbjct3916424   
Query122      
CGGGAAACTGAACAAAGCAATCAGTCGCGGTAATGGCCTGAAAGGCGAGGACTGGACGCA  181         
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGGGAAACTGAACAAAGCAATCAGTCGCGGTAATGGCCTGAAAGGCGAGGACTGGACGCA  3916305 
Sbjct3916364 
Query182      
GAAAGTTAGCTTAATTTCCGCTGTGCCGCAAACCGTTAGCGGGCCTTTAGCCAACAGTAC  241       
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAAAGTTAGCTTAATTTCCGCTGTGCCGCAAACCGTTAGCGGGCCTTTAGCCAACAGTAC  3916245 
Sbjct3916304 
Query242      
GCTTCAGGGGGAAATATTTCTCCAGCGCGAGGGGCATATCCAACAACAAATGGGGGGAAT  301 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCTTCAGGGGGAAATATTTCTCCAGCGCGAGGGGCATATCCAACAACAAATGGGGGGAAT  3916185 
Sbjct3916244 
Query302      
AAATGCCCGCGCAAAAGTTGCTGGCTTGATGATGCGCCAGGACGATAGCGACACGCTGAA  361 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAATGCCCGCGCAAAAGTTGCTGGCTTGATGATGCGCCAGGACGATAGCGACACGCTGAA  3916125 
Sbjct3916184 
 
Query  362       
TTCTCTGGGCGTTTTTGTCTGGGCATGGCCGGATGGACCGCAGTTAATGTCTGATCGTTT  421 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTCTCTGGGCGTTTTTGTCTGGGCATGGCCGGATGGACCGCAGTTAATGTCTGATCGTTT  3916065 
Sbjct3916124   
Query422       
AAAAGAGCTGGCTACCGCAGGTTTTACTCTAACGCAGACGTATACCCGTGCGGTGAAAAA  481 
||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAAAGAGCTGGCTACCGCAGGTTTTACTCTAACGCAGACGTATACCCGTGCGGTGAAAAA  3916005 
Sbjct3916064 
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Query482      
TGCTGATGAAGTTGCGCGCGTACGCAATGAGTGGTGGAAAGCGGAATTACCCTTCGTCAC  541 
||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGCTGATGAAGTTGCGCGCGTACGCAATGAGTGGTGGAAAGCGGAATTACCCTTCGTCAC  3915945 
Sbjct3916004 
Query542      
CGATGGCGTAGTTGTACGAGCGGCGAAAGAGCCAGAATCCCGCCATTGGCTACCGGGCCA  601 
 |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGATGGCGTAGTTGTACGAGCGGCGAAAGAGCCAGAATCCCGCCATTGGCTACCGGGCCA  3915885 
Sbjct3915944 
Query602      
GGCAGAGTGGCTGGTGGCCTGGAAATATCAACCTGTAGCTCAGGTTGCCGAAGTGAAGGC  661 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCAGAGTGGCTGGTGGCCTGGAAATATCAACCTGTAGCTCAGGTTGCCGAAGTGAAGGC  3915825 
Sbjct3915884 
Query662      
AATTCAGTTTGCGGTGGGTAAGAGCGGTAAAATATCGGTGGTTGCGTCACTCGCACCTGT  721 
  |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AATTCAGTTTGCGGTGGGTAAGAGCGGTAAAATATCGGTGGTTGCGTCACTCGCACCTGT  3915765 
Sbjct3915824 
Query722      
CATGCTGGATGATAAAAAAGTCCAGCGGGTGAATATTGGTTCCGTCAGGCGCTGGCAGGA  781 
  ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CATGCTGGATGATAAAAAAGTCCAGCGGGTGAATATTGGTTCCGTCAGGCGCTGGCAGGA  3915705 
Sbjct3915764   
Query  782       
GTGGGATATTGCGCCTGGTGATCAGATTCTCGTCAGCCTTGCCGGTCA-GGTATT  835 
|||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
GTGGGATATTGCGCCTGGTGATCAGATTCTCGTCAGCCTTGCCGGTCAGGGTATT  3915650 
Sbjct  3915704   
Fig. 17: Mega BLAST discontinuous search  
 
 
Localization Scores: 
    Cytoplasmic            0.01 
    CytoplasmicMembrane    0.00 
    Cellwall               0.02 
    Extracellular          9.97 
  Final Prediction: 
    Extracellular          9.97 
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Fig. 18: Prediction of protein localization  
 
I did not investigate how it might be that an E. coli DNA ligase conferred resistance 
to the macrolide azithromycin since these substrates bear no apparent similarity.  
 
3.8 Mutagenesis 
 
Mutagenesis was carried out on the gst gene clone, this was done to create mutant 
libraries from the clone, and to carry out the molecular analysis of such libraries 
whether the mutant(s) of the clone would confer an increase resistance to different 
classes of antibiotics.   
 
3.8.1 Spontanous mutation of the gst clone in E. coli  
 
The plates used for this experiment were incubated in a dark box at 37°C since 
tetracycline is photolabile. Growth was monitored after every 24 hr. Colonies 
appeared on plates with no Cmp after 4 days and growth was found on the 24 µg/ml 
Cmp concentration plates after 6 days. It was therefore possible that mutation took 
place in the clone since the plates without Cmp gave growth 2 days before any growth 
could be found on the plates containing the test antibiotic, also at the higher 
concentrations of 18 µg/ml and 21 µg/ml Cmp there were 400 and 500 colonies of 
pDN1 respectively while there were no growth of pGem-T-easy (the vector control) 
indicating that the growth was inhibited by the presence of the antibiotic. 
 
3.8.2 Spontanous mutation of the gst clone in Rhodococcus erythropolis 
 
The vector pNV18 vector was used used as the vector control in the Gram positive 
organism. The plates containing chloramphenicol had colonies appearing at 20 µg/ml 
after 4 days but there was no growth on the 30 µg/ml Cmp plates even when it was 
incubated further for 9 days. It was observed that mutagenesis could have occurred in 
the clone pBA1 since 43 colnies were found on its plate at 20 µg/ml compared to the 
vector control (pNV18) which gave 17 colonies at the same concentration of the 
antibiotic. 
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3.8.3 Chemical mutagenesis of the clones pDN1 in E. coli and pBA1 in                      
R. erythropolis 
 
The cells were treated with 2% EMS solution in buffer E, incubated for 1 hr, and 
washed with the phosphate buffer before being added to LB + Amp/Kan for overnight 
incubation with chloramphenicol at an increasing concentration. The plates were 
incubated at 37°C and 30°C respectively. There were confluent growth on the control 
plates while pDN1 and pGem-T-Easy (vector control) showed growth only at 18 
µg/ml with 250 colonies on their plates, the same no of colnies found on these plates 
could be due to the fact that mutagenesis did not take place. pBA1and pNV18 (the 
vector control) in the Gram positive organism gave growth at 20 µg/ml concentrations 
of chloramphenicol with 192 colonies and 73 colonies in R. erythropolis ATCC 4277 
respectively. Tables 9 and 10 show the results obtained from these experiments. 
 
3.8.4 Mutagenesis by the use of a mutator strain 
 
This method of mutagenesis involves transformation of the clone into the mutator 
strain which serves as the host cell to introduce mutation into the clone. A pre-culture 
of  E. coli CSH116 (mutD) strain was inoculated into 5 ml LB and incubated 
overnight at 37°C. DNA from pDN1 was transformed into this strain via CaCl2 
method and mutants were selected for on LA Amp100 µg/ml
  
plate supplemented with 
15 µg/ml and 20 µg/ml Cmp, with pGemT-Easy as control.                                                                                 
 
Mini prep was carried out using the transformants from the plate, and the extracted 
DNA was ligated with pNV18 by utilizing the PstI and SphI sites in the vector, 
transformations into the Gram positive strains of R. erythropolis ATCC 4277, R. 
rhodochrous HS6 and HS13 were carried out by the electroporation method. Cells 
were spread on LA Kan 100 µg/ml plates, including the vector and cells only plates. 
The plates were incubated at 30°C and colonies were found after 2 days. Serial 
dilutions up to 10-6 were made to determine the number of colony forming units and 
for the subsequent calculation of the mutation rate.  
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Table 8: Spontanous mutation of pDN1 in E. coli  
Cmp conc. (µg/ml)         No of colonies (pDN1)  No of colonies ( pGem) 
0 Confluent growth Confluent growth 
12 Confluent growth Confluent growth 
15 Confluent growth  40 
18 400 0 
21 250 0 
24 1 0 
27 0 0 
Tet conc. (µg/ml)    
0 Confluent growth Confluent growth 
10 200 400 
12 100 250 
 
 
 
 
Table 9: Chemical mutagenesis of pDN1 in E. coli  
 Chloramphenicol conc.    
(µg/ml)  
No of colonies (pDN1) No of colonies (pGem) 
0 Confluent growth Confluent growth 
18 250 250 
21 0 0 
24 0 0 
27 0 0 
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Table 10: Spontanous and chemical mutagenesis of pBA1 in Rhodococcus  
erythropolis ATCC 4277 
Clone No of  colonies 
(spontanous) 
No of colonies 
(EMS) 
No of colonies     
(10-6 dilution) 
4277 (pBA1) 43 192 388 
4277 ( pNV18) 17 73 187 
HS6 (pBA1) 1 1 168 
HS6 (pNV18) 3 1 127 
HS13 (pBA1) 1 1 104 
HS13 (pNV18) 2 1 96 
 
 
Table 11: Mutagenesis in E. coli CSH116 
Clone No of colonies No of colonies                
(10-6 dilution) 
4277 (pBA1) 1 76 
4277 (pNV18) 3 78 
HS6 (pBA1) 2 56 
HS6 (pNV18) 3 61 
HS13 (pBA1) 1 63 
HS13 (pNV18) 4 69 
 
3.8.5 Mutation rates of the clone pBA1 
 
Following the results obtained from the mutagenesis, it was found that the rate of 
mutation of the clone pBA1 was low by calculating the mutation rates in each of the  
strains used for the experiment.  Thus from the chemical mutagenesis,  the mutation 
rate of the clone in R. erythropolis ATCC 4277 strain was < 5 × 10-7 mutations/cell 
division, and those of   the R. rhodochrous HS6 and HS13 strains were both < 1 × 10-9 
mutations/cell division, while the mutation rates for all the three strains in the mutator 
strain E. coli CSH 116 were < 1 × 10-8. With respect to the results obtained from the 
mutagenesis experiments, I concluded that the methods of mutagenesis employed 
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were not effective in introducing the desired mutations into this gst gene, hence a 
more powerful approach will be required to achieve this objective, and that would be 
error-prone PCR. 
 
3.9 Screening for plasmid borne mutants via marker rescue technique  
 
This technique was carried out to identify the plasmid borne mutations by pooling of 
chloramphenicol resistant colonies. Mini prep was then performed on the culture 
using alkaline-lysis method. The DNA extracted from the clones pDN1 and pNV18 
were transformed into the E. coli MM294-4 strain and cells were spread on LA Amp 
100 µg/ml plates supplemented with concentrations of chloramphenicol used for the 
original selection, pGem-T-Easy and pNV18 controls were included. After an 
overnight incubation, no growth was found on all the plates containing 
chloramphenicol. Plates were left for further incubation period of up to 10 days, but 
there was still no growth. Therefore the mutants obtained were not due to gst but were 
in the E.coli chromosome. 
 
3.10.1 Mutagenesis of the glycosyltransferase gene 
 
A further minor project of mine was based on previous work done in our laboratory, 
C. Lephoto (2002) had cloned and characterized a glycosyltransferase gene – rgt – 
from Nocardia brasiliensis IFM 0236. referred to as pCL1, the plasmid conferred 
resistance to rifampicin. Chemical mutagenesis was also carried out in this clone in 
her work, the result of which was not reported, this could probably be due to the fact 
that mutants were not found after the mutagenesis experiment. 
 
The aim of carrying out this experiment was to utilize an in vitro method of 
mutagenesis  to create  mutants by generating a random point mutation in a given 
segment of the DNA from the clone pCL1, and to investigate the effect of this 
mutation on its resistance to rifampicin as well as other classes of antibiotics. 
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3.10.2 MIC of the glycosyltranferase gene in E. coli 
 
Prior to the mutagenesis, spot tests were carried out to determine the level of 
resistance to rifampicin. Clones obtained from the transformation carried out in E. coli 
MM294-4 were used for the spot test on LA Amp 100 µg/ml plates with an increasing 
concentration of rifampicin up to 400 µg/ml and were incubated at 37°C.                                                                                             
The vector pDA71 in which it was cloned into was used as the vector control. The 
result obtained from the MIC revealed that the clone was resistant to rifampicin at a 
concentration of 400 µg/ml which is about 80 fold increase as was reported before. 
The following chart shows the result obtained from the spot test. 
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Fig. 19: Rifampicin MIC of E. coli due to pCL1 in pDA71   
 
3.10.3 MIC of glycosyltransferase gene in E. coli using pUC18 
 
Following the result found in the vector pDA71, it was imperative to determine the 
MIC of the clone in the vector pUC18 that was used for the epPCR. The insert and the 
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clone were digested with the restriction enzyme PstI and were ligated, followed by 
transformation in to E. coli MM294-4 strain. 
 
The transformants obtained were used to carry out spot tests on LA Amp 100 µg/ml + 
rifampicin at an increasing concentration. Incubation was carried out at 37°C, and 
growth were found after an overnight incubation on the LA Amp plate where 
rifampicin was not present, but no growth was found on the plates containing 
rifampicin, even when incubated further for up to 6 days. 
 
3.10.4 Orientation of the clone pCL1 in pUC18 
 
The reason for the clone not conferring resistance to rifampicin in  pUC18 might be 
due to the fact that pUC18 has the lacZ gene instead of the  promoter found in 
pDA71 which could have favoured the growth of the clone, or  the orientation of the 
clone in the vector was in the opposite direction. Extraction of the DNA was carried 
out for double digestion, and the restriction enzymes SfuI and XbaI that are closest to 
the PstI site of the insert from where it was sitting on both sides of the vector were 
used for the digestion. The digestion was carried out overnight, and run on 0.8% 
agarose gel. 
 
An approximately 1.6Kb size of the insert band was obtained on the gel which gave 
the  possibility that, the enzymes must have cut the vector just  before the PstI site and 
also cut the insert just before the PstI site on the opposite side giving the 
approximately 1.6 Kb size, and not the second possiblity where both could have cut 
very close to just one site of PstI whereby the total size of the area cut would be 
approximately 210 bp. From this result, it was concluded that the insert was cloned in 
the opposite direction to the lacZ gene in pUC18. 
 
3.10.5 Error prone PCR 
 
pCL1 DNA was resuspended in 100 µl of sdH20, and 20 µl of this was diluted with 
100 µl sdH20 to give a concentration of 45.2 ng/µl on the nanodrop. 2.25 µl of this 
concentration was used for the reaction to give a final concentration of 0.1µg in the 
reaction mixture. Error prone PCR was carried out as stated in the materials and 
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method section and several controls were utilized including; standard PCR, fwd 
primer control, rev primer control and no template DNA control. The amplified 
products were checked on 1.2% agarose gel electrophoresis, digestion of the epPCR 
product was carried out with the vector pDA71 for ligation with PstI. 
 
The amplified product of epPCR ligated into pDA71 was transformed into E. coli 
MM294-4 hereafter referred to as pVOA1, mini prep was carried out to check for the 
amplified band on the agarose gel.  The band of interest was excised by a sterile 
scapel and  purified. The concentration of pVOA1 DNA was checked on the 
spectrometer and the DNA was sent to Inqaba Biotec for sequencing. 
 
3.10.6 Sequencing result 
 
The nucleotide sequence result obtained from Inqaba was aligned with the existing 
sequence of pCL1 in the data base using the web tools, and it matched the sequence 
by aligning with the sequence of the N. brasiliensis IFM 0236 from which the 
mutagenesis was carried out. However, multiple mutations occurred in the DNA 
including base pair substitution, insertion, and deletion of the nucleotides. It was 
therefore not suitable for further analysis. 
 
3.11 Antibiotic inactivation assayed on plates 
 
 
Plate inactivation assays were carried out in the Gram negative background using the 
DNA from the clone pDN1, and in the Gram positive background using the DNA 
from the clone pBA1. These were done in order to investigate the concentration of 
chloramphenicol that could be utilized by the DNA from these clones which could 
lead to a novel chloramphenicol inactivation mechanism. 
 
3.11.1 Calibration for inactivation assay 
 
A70 µl volume of chloramphenicol in LB at 2, 4, 8, 16, 32 and 64 µg/ml were added 
to the wells made on LA half agar plates covered with a B. subtilis 1A3-1 lawn. These 
plates were incubated in the cold for 4 hr to allow for antibiotic diffusion before an 
overnight incubation at 37°C. Diameters of the zones of inhibition were measured on 
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the plates to plot a calibration curve where the zones of inhibition obtained from the 
inactivation assays performed in E. coli and Rhodococcus strains were compared. The 
results obtained from the calibration experiment is presented in fig 20 below. 
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Fig. 20: Calibration curve for chloramphenicol concentration 
 
3.11.2 In vivo inactivation in E. coli and Rhodococcus 
 
 E. coli clones were grown overnight at 37°C while Rhodococcus clones were grown 
for 2-3 days for in vivo inactivation assays. A 100 fold dilution of these cultures were 
made and chloramphenicol at 10 µg/ml concentration was added to each culture for 
overnight incubation. 
 
A 1:100 fold dilution of B. subtilis 1A3-1, the assay organism was made and spread 
on  LA half agar plates to which 200 µg/ml streptomycin had been added. Wells  were 
made on the plates and a 70 µl volume of the cultures were added to the wells. 
Plasmid pACYC184 (which inactivates chloramphenicol due to the acetyl-transferase) 
and pGemT-Easy were used as controls in E. coli, while transformant Rhodococcus 
pNV18 (vector only) was a the negative control. After 4 hr in the cold to allow 
diffusion, incubations were carried out at 37°C for the E. coli strain, and 30°C for the 
Rhodococcus strain, diameters of the zones of inhibition were measured. Partial 
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inactivation were obtained with the gst clones, while pACYC184 showed complete 
inactivation, as expected (table 12). 
 
 
Table 12: Results of in vivo plate inactivation assay 
Cell cultures and antibiotic Diameter of the zones of 
inhibition(mm) 
pDN1 20 
pGem-T Easy 25 
pACYC184 0 
LBCmp 30 
pBA1 14 
pNV18 23 
LBCmp 30 
    
 
3.11.3 In vitro inactivation in E. coli and Rhodococcus 
 
E. coli and Rhodococcus cultures were centrifuged to pellet the cells at 15,000 rpm for 
5 min and the residual antibiotic were removed from the cells by washing with the 
sonication buffer. Crude cell extracts were obtained by sonication and clarified 
supernatants were obtained by spinning down in the cold. Reaction mixtures were set 
up using GSH as the cofactor and acetyl CoA as the co-enzyme to transfer the acetyl 
group in to the reaction. After an incubation period of 16 hours, the reaction was 
stopped by boiling for 10 min and 70 µl of the reaction mixture was added to the 
wells on the half agar plates spread with assay organism. The plates were incubated in 
the cold for 4 hr before an overnight incubation at 37°C.  
 
Cell homogenates from pGemT-Easy and pACYC184 were included for the reaction 
in E.coli and  pNV18 for Rhodococcus, this is to ensure that the chloramphenicol 
phenotype obtained was due to the gst in pDN1 and pBA1 respectively, while  LB + 
Cmp was used as the negative control. Diameters of the zones of inhibition were 
measured to compare the level of inactivation shown by the clones. 
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From the results obtained, the clone pBA1 in Rhodococcus showed partial 
inactivation compared to the clone pDN1 in E. coli. This suggests that this could be a 
novel chloramphenicol inactivation mechanism since there are no reports in the 
literature of GST-mediated inactivation of this drug. Figure 21 shows the results 
obtained from the inactivation plates, while the diameters of the zones of inhibition 
measured are presented in the table that follows.  
 
Table 13: Results of in vitro plate inactivation assay 
Crude cell homogenates Diameter of zone of inhibition (mm) 
pDN1 23 
pGem-T Easy 27 
pACYC184 0 
LBCmp 30 
pBA1 1.5 
pNV18 24 
LBCmp 30 
  
 
 
                             A                                                                           B 
Fig. 21: In vitro inactivation assays in E. coli (plate A) and Rhodococcus (plate B) 
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3.12 Discussion 
 
3.12.1 Expression of the gst gene in E. coli and Rhodococcus strains 
 
It has been reported that majority of mycobacterial promoters function poorly in E. 
coli, and this is mainly due to the differences in their sigma factor sub regions which 
reflect different hexamer specificities. There has also been a suggestion that low GC 
content may impose a selective pressure for RNA polymerase with higher specificity 
for more conserved AT-rich promoters, therefore organisms like mycobacteria with 
high GC content in the chromosome could be characterized by having less specific 
RNA polymerase than that of organisms with lower GC content, and this can further 
explain why mycobacterial genes are, in general, better expressed in the Gram 
positive strains (Bashyam et., al. 1996; Fernandes et. al.,1999; Manganelli et. al., 
1999). 
 
In this work, the expression of M. smegmatis mc2155 gst gene was poor in E. coli. 
Rich media were used to characterize the antibiotic resistance phenotype in E. coli at 
varying degrees of temperature, and the slightly increase in MIC observed could have 
been triggered by a sigma factor. This is because no noticeable increase was found at 
lower temperatures, and the effect of media differences was not of noticeable impact 
on the phenotype. In the Gram positive background changes in MIC were greater. 
Therefore future works should to be carried out in R. erythropolis ATCC 4277 where 
the gene expressed the best phenotypes.  
 
3.12.2 Chloramphenicol resistance phenotype 
 
Known resistance to chloramphenicol may be due to the cat gene (chloramphenicol 
acetyl-transferase). The product of the gene catalyzes the transfer of acetyl group 
from acetyl coenzymeA to chloramphenicol to form monoacetylated (1-acetyl and 3-
acetyl chloramphenicol) and diacetylated (1, 3 diacetyl chloramphenicol) derivatives. 
Studies carried out in the Gram positive background revealed that spontaneous 
resistance to chloramphenicol occurs in mycobacteria at a frequency of 10-4 and can 
give rise to false positive clones (Bashyam et. al., 1996). From my experiments, it was 
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observed that the gst gene from M. smegmatis mc2155 gave a well defined increase in 
MIC in the Gram positive.   
 
3.12.3 Resistance to other structurally unrelated antibiotics  
 
Resistance to the aminoglycosides is mainly due to genes exchanged on plasmids and 
transposons. With respect to the antibiotics tested in this work, this class of antibiotics 
gave the best increase in MIC. Streptomycin, Spectinomycin and Kanamycin all gave 
a 3 fold increase in E. coli, it was only kasugamycin that gave a < 2× MIC increase in 
this strain and this is not surprising because it is considered the weakest of them all. In 
the Gram positive strains these antibiotics still gave the best increase in MIC 
especially in   R. erythropolis where streptomycin and spectinomycin both gave a 5× 
increase in MIC, kasugamycin gave a 4 fold increase while Kanamycin was not tested 
in this strain as it was used as the selectable marker. 
 
Resistance to the antibiotic erythromycin was very poor in all the strains used in this 
work. The increase in MIC was < 2 fold in all the strains and this could be due to the 
fact that the antibiotic was able to bind to the region of the ribosome where some 
degree of inhibition could have occurred, and that the gst gene did not express the 
enzyme methylase that could have prevented the binding of the antibiotic to the 
region of the ribosome, the plasmid that would have encoded this characteristic might 
not be present in the gene.  
 
Resistance phenotype to Nal was poorly expressed in E. coli with a < 2× increase in 
MIC, but it gave one of the best results in R. erythropolis with a 5 fold increase. It 
could therefore be possible that the enzyme responsible for resistance in this antibiotic 
could not be activated in E. coli.  
 
3.12.4 Mutagenesis 
 
Since spontaneous mutation and chemical mutagenesis of the gst gene did not give 
rise to any mutant after marker rescue, mutagenesis by the use of a mutator strain E. 
coli CSH116 was employed. Its plasmid encodes a non-functional mutant of the mutD 
gene, and it was expected that this would produce mutants in thousands fold. The 
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result from this experiment was quite disappointing as only 1 colony was obtained 
from R. erythropolis while HS6 and HS13 gave 2 colonies and 1 colony respectively. 
It was therefore concluded that none of the methods of mutagenesis employed could 
give the expected plasmid borne mutant. 
 
 3.12.5 Inactivation assays 
 
Preliminary work explored the possibility of obtaining a novel chloramphenicol 
inactivation phenotype from the cloned gst gene fragment. Partial inactivation was 
found on the in vitro assay plate of the clone pBA1, the diameter of the zone of 
inhibition was measured at 1.5 mm compared with the cell homogenate from the 
vector control which gave the zone of inhibition of 24 mm, and 30 mm for the 
antibiotic control. This is an indication that further work could be done to achieve the 
objective of cloning and characterizing the chloramphenicol inactivation phenotype 
from the gst gene DNA. 
 
3.12.6 Future work 
 
Different methods of mutagenesis techniques were employed to create a plasmid 
borne mutant from the gst gene DNA which did not yield the desired result. A more 
powerful in vitro mutagenesis method by the error prone PCR is therefore suggested 
to create point mutation in the DNA. A mutant library is to be created for the 
molecular analysis by carrying out the sequencing, cloning and characterizing the 
DNA to obtain the inactivation phenotype as well as carrying out the biochemical 
analysis for the determination of the protein(s) that the mutant encodes.  An 
explanation needs to be sought for the apparent conferral of azithromycin resistance 
by E. coli DNA ligase.  
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CHAPTER 4 
 
 
 
APPENDICES 
 
 
 
APPENDIX A 
 
 
 
GROWTH MEDIA: 
 
 
 
LB (100 ml) 
 
Tryptone            1g 
Yeast extract      0.5g 
            NaCl                   0.5g 
 
 
 
LA (100 ml) 
 
Tryptone           1g 
Yeast extract     0.5g 
NaCl                  0.5g 
Agar                  1.5g 
 
 
LA ½ Agar (100 ml) 
 
Tryptone           1g 
Yeast extract     0.5g 
NaCl                  0.5g 
Agar                  0.75g 
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LBSG (100 ml) 
 
Tryptone           1g 
Yeast extract     0.5g 
            NaCl                  0.5g 
            Sucrose              10g 
            Glycine:            1g for 1% 
                                      2g for 2% 
                                      3g for 3% 
 
 
LBG (100 ml) 
 
Tryptone           1g 
Yeast extract     0.5g 
            NaCl                  0.5g 
            Glycine              2g 
 
Autoclave for 20 min at 121°C. For LBSG, sucrose was dissolved in water by 
microwave before adding other components; it was then made up to 100ml. LB was 
stored at 4°C, while LBSG and LBG were stored at -20°C and melted in the 
microwave before use. 
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APPENDIX B 
 
 
SOLUTIONS 
 
Solutions for E. coli mini plasmid preparation 
 
Solution 1 
            50 mM glucose 
25 mM Tris-HCl 
10 mM EDTA  
             pH 8.0 
 
Solution 2 
           0.2 M NaOH 
           1.0% SDS 
 
Solution 3 
            5 M potassium acetate pH 4.8 
88.5 ml sdH2O  
11.5 ml glacial acetic acid 
 
Ribonuclease 
           10 mg/ml RNase dissolved in sdH2O 
           Boil at 100°C for 10 min before use 
 
Deoxyribonuclease 
           10 mg/ml solution in sdH2O  
           Boil at 95°C immediately before use    
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Solutions for Rhodococcus mini plasmid preparation  
 
TE buffer 
           0.5M EDTA 
           1M Tris-HCl 
pH 8.0  
 
TE lysozyme 
            TE + 5mg/ml lysozyme 
 
TE SDS  
           TE + 10% SDS 
 
5.0 M KAc (pH6.0) 
 
Solutions for E. coli calcium chloride-mediated transformation 
             
CaCl2 transformation buffer 
             
            20 mM Tris-HCl 
100 mM CaCl2 
             pH 7.6-8.0 
 
20% glucose 
 
4g glucose 
            20 ml dH2O 
 
Autoclave for 20 min at 121°C. 
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Solution for agarose gel electrophoresis 
 
5× TBE 
            54.0 g Tris 
27.5 g boric acid 
20 ml 0.5 M EDTA pH 8.0 
 
Add distilled water to 1 litre, mix and autoclave at 121°C for 20 min.  
 
Running buffer (0.5× TBE) 
25 ml 5× TBE 
225 ml sdH2O 
            25 µl EtBr 
 
Agarose gels (200 ml): 
          1.6g agarose = 0.8% 
          2.4g agarose = 1.2%  
          20 ml 5× TBE 
          180 ml sdH2O 
 
Dissolve the agarose in the microwave. 25 ml was used for each gel, and 25µl of 
ethidium bromide (10 mg/ml) was added. 
 
Tracking dye 
 
30% glycerol (w/v) in TE 
            0.025% bromophenol blue 
 
 
 
 
 
 
 
 78 
Solutions for inactivation assay 
 
Sonication Buffer 
           2.0 ml 1 M Tris-HCl pH 7.2 
           100 µl 0.5 M EDTA 
           100 µl 1 M DTT 
           97.8 ml dH2O 
 
Autoclave before use (121°C, 20 min) and store at 4°C. 
 
LDR 1 g/ml each 
 
Solutions for chemical mutagenesis 
        
Buffer E            
           10× A-N buffers diluted 1:10 
 
10× A-N buffer 
           70g K2HPO4 
           26.8g KH2PO4 
           5.0g Na3C6H5O7 (tri-sodium citrate) 
           1.0g MgSO4 
 
Add distilled water to 1 litre 
 
 
 
 
 
 
 
 
 
 79 
APPENDIX C 
 
 
Antibiotics used in this work 
 
 
ANTIBIOTICS STOCK (mg/ml) SOLVENT SUPPLIER 
Ampicillin 100  Ethanol 70%, 
water 30% 
Boehringer 
Mannheim  
Azithromycin 10  Ethanol 70%, 
water 30% 
Unmarked 
Chloramphenicol 4  Ethanol Boehringer 
Mannheim 
Chlortetracycline 10  Methanol Sigma 
Erythromycin 20  Ethanol 70%, 
Water 30% 
Boehringer 
Mannheim 
Fusidic acid 10  Ethanol Leo 
pharmaceutical  
Kanamycin 100  Water Boehringer 
Mannheim 
Kasugamycin 10  Water Boehringer 
Mannheim 
 
Nalidixic acid 100  Ethanol 70%, 
Water 30% 
Sigma 
Rifampicin 10  Methanol Sigma 
Spectinomycin 20  Water Sigma 
Streptomycin 20  Water Boehringer 
Mannheim 
Oxytetracycline 10  Methanol Sigma 
Tetracycline 20  Methanol Sigma 
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APPENDIX D 
 
 
Calculation of mutation rate 
 
Mutation Rate =  No. of resistant cells/ml  
                             Total no. of cfu/ml  
 
Cfu/ml =   No. of colonies on the LA plate × dilution factor 
                 Vol. of the culture spread on the plate 
 
 
No. of resistant cells/ml =  No. of antibiotic resistant colonies  
                                           Vol. of the culture spread on the plate 
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APPENDIX E 
 
 
Restriction maps of plasmids  
 
                                   
 
http://seq.yeastgenome.org/vectordb/vector.html 
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http://www.fermentas.com/techinfo/nucleicacids/mappuc1819.hth 
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Adapted from www.promega.com, technical manual No. 042) 
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www.fermentas.com/techinfo/nucleicacids/mappacyc184.htm 
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http://nocardia.nih.go.jp/vectors 
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